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Congenital muscular dystrophy with megaconial myopathy (MDCMC) is an autosomal
recessive disorder characterized by progressive muscle weakness and wasting.
Megamitochondria in skeletal muscle biopsies and cognitive impairments in MDCMC patients
are observations exclusive to this type of muscular dystrophy. The disease is caused by loss of
function mutations in the choline kinase beta (CHKB) gene which results in dysfunction of the
Kennedy pathway for the synthesis of phosphatidylcholine (PC). A rostro-caudal muscular
dystrophy (rmd) mouse with a deletion in the Chkb gene resulting in MDCMC-like symptoms
has been reported by our lab. In order to test if the rmd mice show signs of cognitive
impairments as observed in MDCMC patients, I engineered a transgenic rmd mouse model (Tgrmd) which I used for MS/MSALL mass spectrometry analysis of brain tissue and to test for
working memory and learning impairments. These tests show us that even though Tg-rmd mice

showed significantly different lipid profiles in brain, these changes were not translated in the
behavioral assays conducted.
I have worked on the development of and tested gene therapy strategies for the rescue
and alleviation of dystrophy symptoms using the rmd mouse model. I have observed that
introduction of a muscle-specific Chkb transgene completely rescues motor and behavioral
function in the rmd mouse model, confirming the cell-autonomous nature of the disease.
Intramuscular gene therapy, post-disease onset, using an AAV6 vector carrying a functional copy
of Chkb gene is capable of rescuing the dystrophy phenotype in rmd mice. In addition,
upregulating choline kinase alpha (Chka), a gene paralog of Chkb, via a similar AAV6 viral
vector showed increased muscle regeneration and alleviation of muscular dystrophy symptoms
as was observed with Chkb AAV injections.
Together, my results suggest rmd mice do not model the cognitive impairments observed
in MDCMC patients and that replacement of the Chkb gene or upregulation of endogenous Chka
could serve as potential lines of therapy for MDCMC patients.
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DEDICATION

My work is dedicated to those burdened by Congenital Muscular Dystrophy with Megaconial
Myopathy.
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CHAPTER 1
A REVIEW OF CONGENITAL MUSCULAR DYSTROPHY WITH MEGACONIAL
MYOPATHY (MDCMC)

“Sometimes my body wakes me up and says
‘Hey, you haven’t had pain in a while. HOW ABOUT PAIN?’
And sometimes
I can’t breathe,
And that’s hard to live with.
But I still celebrate life and
DON’T GIVE UP”
-

Mattie Stepanek, poet, philosopher, victim of muscular dystrophy.

An Introduction To Congenital Muscular Dystrophy (CMD)
The Muscular Dystrophy Association (MDA) defines muscular dystrophy (MD) as a group of
diseases characterized by progressive muscle weakness or hypotonia and loss of muscle mass
(www.mda.org). Muscular dystrophy is caused by inherited and occasionally spontaneous
genetic mutations, the symptoms of which, are identified at a different time points in individuals
depending on the gene involved and type of mutation. Muscular dystrophies can be classified
into 55 different genetic forms which can affect both males and females, leading to skeletal
muscle degeneration and loss of motor strength that affecting walking, breathing, swallowing
and may also include cardiomyopathy (www.mda.org, www.ninds.nih.gov). Many of these
dystrophies present themselves at birth with rapidly progressing symptoms. These early-onset
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muscular dystrophies, more specifically defined as a heterogenous group of disorders
characterized by disease onset at birth with rapidly progressing symptoms are termed as
Congenital Muscular Dystrophies (CMD) (S. E. Sparks & Escolar, 2011) . To date, there are
approximately 30 different types of CMD reported, each based on the gene or protein affected.
Most CMD’s reported so far arise as a result of an autosomal recessive mutation in the gene that
codes for a member of the group of extracellular matrix proteins like collagen, laminin,
dystroglycan and integrin. According to statistics provided by the National Organization of Rare
Disorders, the exact incidence and prevalence of CMD in the world is not known. A study of the
population of Italy reported an incidence of 1 in 125,000 whereas another study based on the
population in western Sweden based the prevalence of CMD at 1 in 16,000. CMD is estimated
to affect about 250,000 Americans with the Italian population in particular shows an incidence
and prevalence of 1 in 4.65 X 105 and 8 X 106 in the North East (Mercuri, Sewry, Brown, &
Muntoni, 2002). Some forms of CMD are highly prevalent in certain parts of the world with
Laminin alpha-2 deficiency and collagen VI-deficient CMDs being the most common subtypes
in many countries with populations of European origin. However, due to failure in diagnosis of
primary muscle disease in individuals with mild muscles weakness, with or without intellectual
disability may continue to result in underestimation of the prevalence of CMD (S. Sparks et al.,
2012).

Congenital Muscular Dystrophy with Megaconial Myopathy (MDCMC)
In the year 1998, a group of Japanese doctors reported 4 patients suffering from an unusual form
of muscular dystrophy that displayed the presence of giant mitochondria or megamitochondria in
muscle biopsies (Nishino et al., 1998). These patients had unaffected parents and siblings,
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indicating that this was an autosomal recessive genetic disorder. Since the phenotype of
megamitochondria had not been observed in the spectrum of MD diseases, these patients were
not classified into any MD subtype and the genetic cause was unknown. Histologic examination
of muscle biopsies showed that the megamitochondria were situated at the periphery of muscle
fibers just under the sarcolemma and mitochondria were absent from the central regions of the
sarcoplasm. A second biopsy from one of the 4 patients taken at 13 years (after a 12 year interval
from the first biopsy) showed that the peripheral location of the megamitochondria did not
change with time. All patients showed elevated serum creatinine kinase (CK) levels and an
increased proportion of necrotic and regenerating fibers with age, indicating an increase in the
progression of dystrophy. Since megamitochondria was a prominent phenotype, patient
mitochondrial DNA was analyzed for the presence of mutations. None of the patients showed
deletion or duplication mutations in mitochondrial DNA, indicating that the mitochondrial
phenotype was likely caused by mutation of a nuclear gene. In addition to this, serum lactate
levels and respiratory chain enzyme activities were normal, providing further indication that the
dystrophic phenotype was not due to alterations in mitochondrial DNA (mtDNA) sequence.
Together, this suggested that the disease was unlike any of the previously reported merosin
positive or dystrophin-glycoprotein complex dystrophies.
In 2006, a spontaneous recessive mouse mutation leading to a progressive muscular
dystrophy with a rostral-to-caudal gradient of severity and a neonatal bone deformity was
identified by the Cox lab at The Jackson Laboratory. This mouse was termed as rmd, to indicate
the increasing gradient of severity of the muscular dystrophy in a rostral to caudal fashion (Sher
et al., 2006). Positional cloning identified a 1663 bp genomic deletion encompassing exon 3 to
intron 9 in mouse choline kinase beta (Chkb) gene on chromosome 15. Transcription of the gene
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would encode a truncated CHKB protein in which the choline binding and active sites were
removed. Choline kinase beta is an important enzyme in the Kennedy pathway of skeletal
muscles, playing an important role in the first-step conversion of choline to phosphocholine and
subsequently into phosphatidylcholine (PC) (Gibellini & Smith, 2010). The rmd mutant mice lost
significant control of hindlimb motor activity as indicated by dragging of hindlimbs at 2-3
months of age. Histological examination of quadricep muscles from mice aged 6, 14, 26 and 59
days, revealed presence of megamitochondria and significantly increased number of centralized
nuclei in the hindlimb muscles of rmd mice. Interestingly, forelimb muscles showed sparse but
not significant numbers of megamitochondria and no significant number of centralized nuclei on
comparison with unaffected C57BL/6J littermates (WT mice). Membrane integrity testing using
Evans Blue Dye, suggested that the muscular dystrophy was not likely the result of impaired
sarcolemmal integrity. Testing for amounts of phosphatidylcholine and
phosphatidylethanolamine (PE) levels in muscle tissue from fore and hindlimbs showed no
significant changes in PE levels but a 38% decrease in PC levels in the forelimbs and 31% in the
hindlimbs, suggesting that absolute levels of PC, alteration in the distribution of PC species or
changes in PC:PE ratio are crucial to the progression of dystrophy symptoms in rmd mice. The
gradient in the severity of dystrophy symptoms was thought to result from a differential ability of
tissues to compensate for a loss of choline kinase beta protein. This observation was further
corroborated by Wu. et. al. in 2009 and 2010 where they showed that there exists a tissuespecific distribution of enzymes like citidyltransferease (CT), the rate limiting enzyme in the
Kennedy pathway. When CT activity is significantly reduced in hindlimbs of rmd mice it impairs
PC synthesis resulting in a decrease in PC levels in hindlimbs of rmd mice. This decrease can
also be explained by a >2 fold increase in PC catabolism and turnover in the hindlimb skeletal
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muscles. There is a greater percent contribution of mitochondrial PC to total muscle PC in the
hindlimb skeletal muscles, which may result in the mitochondria diverting PC from the
sarcolemma and contributing it to the muscular dystrophy, thus also adding to the increased
mitochondrial dimensions (Wu, Sher, Cox, & Vance, 2009). This adds to impaired mitochondrial
function in rmd mice where a 40% lower mitochondrial inner membrane potential is observed
indicating compromised mitochondrial function. Together, these results indicate that a
deficiency in PC results in muscular dystrophy phenotype in rmd mice. In WT mice,
megamitochondria may form in response to an increase in intracellular reactive oxygen species
(ROS), where the mitochondria try to decrease this increase in ROS levels by decreasing
consumption of oxygen by formation of megamitochondria. Megamitochondria can also lead to
apoptotic signals in unfavorable cellular environments, thus protecting the organism
(Wakabayashi, 2002). Thus, in short-term, megamitochondria are considered protective to the
organism. However, in the longer-term megamitochondria formation compromises
mitochondrial function (Wu et al., 2009). These studies accelerated MDCMC research by
characterizing the biochemical influences that lead to muscular dystrophy symptoms and
phenotype in rmd mice.
Muscles of the forelimbs of the rmd mice did not show as many megamitochondria and
had relatively normal fiber structure and architecture compared to hindlimb skeletal muscles.
The mechanism by which the severity of muscular dystrophy phenotype was greater in the
skeletal muscles of the hindlimbs of rmd mice whereas the forelimbs remained relatively less
affected remained unclear until 2010, when it was reported that Chkb deficiency did not impair
PC synthesis in the forelimb of rmd mice (Sher et al., 2006)(Wu, Sher, Cox, & Vance, 2010).
This is because choline kinase alpha (Chka), a gene paralog of choline kinase beta gene, can
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compensate for lack of choline kinase beta. Chka and Chkb have evolved from a process of
duplication and divergence from a common ancestral gene (Aoyama, Liao, & Ishidate, 2004).
Western and northern blot analysis showed that both Chka and Chkb mRNA’s and proteins are
expressed ubiquitously and concurrently in most mouse tissues. Subsequent immunoprecipitation
showed that CHKA and CHKB proteins may function as homodimers or heterodimers but the
predominant part of choline kinase (CK) activity is as a a-b heterodimer. In vitro studies with
COS-7 cells co-transfected with HA-tagged CHKA or CHKB along with a Myc-tagged
counterpart suggested that the activity of CK in each cell type is regulated by the level of each
isoform along with the combination of each isoform subunit to generate the active dimer
complexes (Aoyama et al., 2004). Approximately 70% of the total CK activity in the skeletal
muscles of forelimb of mice is governed by CHKA whereas 80% of the total CK activity in the
hindlimb skeletal muscles is governed by Chkb (Wu et al., 2010b). This explains why in the
absence of Chkb, the forelimbs of rmd mice are less affected and why there is a gradient of
severity of muscular dystrophy phenotype in these mice. Immunoblots of muscles from fore and
hindlimbs of WT mice at 1, 3 and 8 weeks of age suggests that with an increase in age of the
mouse, Chka expression increases in the forelimbs and decreases in the hindlimbs. In contrast,
Chkb expression increases significantly in the hindlimb skeletal muscles of WT mice (Wu et al.,
2010). The residual expression of CHKA could explain why the muscular dystrophy is less
evident in forelimbs of rmd mutant mice. Together, these results indicate that there is a
rostrocaudally defined developmental heterogeneity in a number of factors responsible for the
development of vertebrate skeletal muscle and that these factors also play an important role in
defining the pattern and severity of muscular dystrophy symptoms in rmd mice.
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Post identification of the rmd mouse, the patients identified by Nishino et al. in 1998
were sequenced and it was found that all of them showed mutation in the CHKB gene that lead to
muscular dystrophy, megamitochondria and severe cognitive impairments. These patients were
classified as congenital muscular dystrophy with megaconial myopathy (MDCMC) (Mitsuhashi,
Ohkuma, et al., 2011). Following this, many more cases of MDCMC were reported. These
results suggest that the rmd mouse is a good model for the study of MDCMC in humans,
providing an excellent starting point for my experiments towards further characterization of the
disease and towards designing strategies of functional rescue.

The Kennedy pathway and its implications in MDCMC
The Kennedy pathway elucidated in 1956 by Kennedy Weiss describes the pathway for the de
novo synthesis of PE and PC. There are two branches of the Kennedy pathway based upon the
formation of characteristic high-energy intermediates-CDP-ethanolamine, for the synthesis of PE
and CDP-choline, for the synthesis of PC. Hence, the two branches of the Kennedy pathway are
often referred to as CDP-ethanolamine and CDP-choline pathway (Gibellini & Smith, 2010).
In the CDP-ethanolamine Pathway, the first step is initiated by the ATP-dependent
phosphorylation of ethanolamine to phosphoethanolamine. The second step, also the ratelimiting step, involves CTP:phosphoethanolamine cytidyltransferase (ECT) using
phosphoethanolamine and CTP to form high-energy donor CDP-ethanolamine with the release of
pyrophosphate. The third and final steps involves CDP-ethanolamine:1,2-diacylgycerol
ethanolaminephosphotransferase using CDP-ethanolamine and a lipid anchor like Diacylglycerol
(DAG) to form PE and CMP as byproducts. Analogous CDP-choline pathway is also a 3 step
pathway, using a series of similar reactions to form PC. In the CDP-choline pathway, choline
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kinase instead of ethanolamine kinase catalyzes the first step phosphorylation of choline to
phosphocholine. Similarly, cytidine-diphosphate and CDP-choline cholinephosphotransferase are
the enzymes that catalyze the second and third step of the CDP-choline pathway (Gibellini &
Smith, 2010). In mammals, there are three isoforms of choline kinase-choline kinase alpha 1 and
choline kinase alpha 2 synthesiszed by the same gene and choline kinase beta synthesized by a
gene paralog. Ethanolamine kinase has two isoforms- ethanolamine kinase 1 and ethanolamine
kinase 2 (Hong et al., 2010)(Gibellini & Smith, 2010).
The enzymes of the Kennedy pathway can overlap in substrate usage. In mammals,
choline kinase isoforms that are able to phosphorylate enthanolamine have been identified
(Gibellini & Smith, 2010). In mammals, CDP-choline pathway is predominant for the synthesis
of PC in all tissues except the liver where significant amount of PC is made by methylation of
PE. It has been reported that phospholipid methytransferase activity in non-hepatic tissues is
extremely low relative to CDP-choline pathway activity (Kent, 1995). This in-turn indicates that
synthesis of PC in skeletal muscles is predominantly dependent on the CDP-choline branch of
the Kennedy pathway.
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FIG 1: The CDP-choline branch of the Kennedy pathway.
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CHAPTER 2
FUNCTIONAL RESCUE OF CONGENITAL MUSCULAR DYSTROPHY WITH
MEGACONIAL MYOPATHY IN A MOUSE MODEL OF THE DISEASE.

Abstract:
Congenital muscular dystrophy with megaconial myopathy (MDCMC) is an autosomal recessive
disorder characterized by progressive muscle weakness and wasting. The observation of
megamitochondria in skeletal muscle biopsies is exclusive to this type of muscular dystrophy.
The disease is caused by loss of function mutations in the choline kinase beta (CHKB) gene
which results in dysfunction of the Kennedy pathway for the synthesis of phosphatidylcholine
(PC). We have previously reported a rostro-caudal muscular dystrophy (rmd) mouse with a
deletion in the Chkb gene resulting in MDCMC-like symptoms, and we used this mouse to test
gene therapy strategies for the rescue and alleviation of dystrophic symptoms. Introduction of a
muscle-specific Chkb transgene completely rescues motor and behavioral function in the rmd
mouse model, confirming the cell-autonomous nature of the disease. Intramuscular gene therapy
post-disease onset using an AAV6 vector carrying a functional copy of Chkb is also capable of
rescuing the dystrophy phenotype. In addition, we examined the ability of choline kinase alpha
(Chka), a gene paralog of Chkb, to improve dystrophic symptoms when upregulated in skeletal
muscles of rmd mutant mice using a similar AAV6 vector. The sum of our results in a preclinical
model of disease suggest that replacement of the Chkb gene or upregulation of endogenous Chka
could serve as potential lines of therapy for MDCMC patients.
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Introduction:
Congenital muscular dystrophies (CMDs) are a group of autosomal recessive disorders
exhibiting muscle weakness, wasting and hypotonia at or soon after birth with progressively
increasing symptoms (Mercuri et al., 2002). There are currently at least 30 different types of
CMD. In 2006, we reported a spontaneous mouse mutation displaying muscular dystrophy in a
rostral to caudal gradient, with its hindlimbs being more affected than its forelimbs coupled with
the presence of giant/mega mitochondria, leading us to name it rostrocaudal muscular dystrophy
(rmd)(Sher et al., 2006b). The rmd mouse carries a 1.6kb deletion in the choline kinase beta
(Chkb) gene, resulting in complete loss of CHKB activity. Choline kinase beta is an important
enzyme in the Kennedy pathway, required for de-novo synthesis of phosphatidylcholine. In
mammals, choline kinase is the enzyme in the first step conversion of choline to phospho-choline
which is ultimately converted to phosphatidylcholine (PC), one of the four major biolipids in all
cellular membranes (Gibellini & Smith, 2010). In mammals, choline kinase activity is encoded
by two separate paralogous genes, choline kinase alpha (Chka) and choline kinase beta (Chkb),
which function either as homo- or hetero-dimers. Both of these genes have wide tissue
expression profiles and both encoded enzymes phosphorylate choline to phosphocholine.
Following the publication of the rmd mouse model, a group of 15 patients with
congenital muscular dystrophy and mega mitochondria were sequenced and found to contain loss
of function mutations in the CHKB gene. The disease was classified as Congenital Muscular
Dystrophy with Megaconial Myopathy (MDCMC), OMIM: 602541 (Mitsuhashi, Hatakeyama, et
al., 2011). Both MDCMC patients and mice have loss of function mutations in the CHKB or
Chkb gene and develop progressive muscular dystrophy indicates that the rmd mice have good
face and construct validity as models of MDCMC. To date, there are at least 48 reported cases of
MDCMC worldwide. These were children born of unaffected parents and having none or one
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affected sibling, indicating an autosomal recessive inheritance. In all reported cases, patients
showed generalized muscle weakness starting at about 5 years of age. Some patients were
reported as early as 22 months of age. These patients missed all major motor milestones and
showed speech defects, with initial speech occurring at about 5 years of age and pronounced
cognitive impairments at about 12 years of age. Many of these patients were first reported due to
floppiness and increased tendencies to fall while walking or running and /or due to the presence
of diffuse skin disorders like mild ichthyosis (Nishino et al., 1998)(Mitsuhashi, Ohkuma, et al.,
2011)(Quinlivan et al., 2013)(Castro-Gago et al., 2014)(Oliveira et al., 2015)(Castro-Gago et al.,
2016)(Brady, Giri, Provias, Hoffman, & Tarnopolsky, 2016)(Gutiérrez Ríos et al.,
2012)(Cabrera-Serrano et al., 2015)(Haliloglu, Talim, Sel, & Topaloglu, 2015).
Here we test several methods of functional rescue of dystrophy using the rmd mouse
model. These tests included examining the effects of dietary intervention with CDP-choline, a
downstream compound of the Kennedy pathway, in an effort to circumvent the defects in the
pathway. We also tested pre- and post-disease onset upregulation of CHKB in the rescue of
muscular dystrophy phenotype in the rmd mutant mice. Pre-disease onset rescue of rmd was
tested by overexpression of the Chkb gene in an engineered muscle-specific transgenic mouse
where Chkb expression was driven by the Titin (Ttn) gene promoter in the skeletal and cardiac
muscles. These Tg-rmd mice also allowed us to examine the cell-type specificity required for
rescue of muscular dystrophy. Post-disease onset rescue was tested by intramuscular injections
of adeno-associated viral (AAV) vectors expressing either the Chka or Chkb genes in rmd mutant
mice. Expression of the Chka gene normally shuts down during postnatal muscle differentiation
(Wu, Sher, Cox, & Vance, 2010a) and our previous work suggested that residual CHKA activity
in anterior muscle groups of the rmd mouse correlated with reduced severity of dystrophic
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symptoms (Wu et al., 2010a). Thus, we sought to determine if CHKA could compensate for the
lack of choline kinase beta as an alternative rescue mechanism in rmd mice. We found that viral
delivery of Chka was also efficacious with comparable potency to rescue with the Chkb gene.

Results
Muscle-specific expression of Chkb transgene prevents muscular dystrophy: We engineered
a full-length cDNA of the mouse Chkb gene under the control of the muscle-specific titin
promoter and created a line of transgenic rmd (Tg-rmd) mice (Fig 2A) (Maddatu et al., 2005a).
The Ttn-Chkb transgene was also carried on a wild-type background. The Tg-rmd and Tg-WT
mice were physically indistinguishable from their wild-type littermates at birth and through
adulthood (Fig 2B and 2E). Real-time PCR assays on tissue from gastrocnemius muscle of Tgrmd, Tg-WT, rmd and +/rmd mice was performed to assess the levels of Chkb cDNA expression.
We observed 18-fold higher expression of Chkb mRNA levels in the Tg-rmd muscles, compared
to C57BL/6J controls, with no detectable levels in mutant rmd muscle, a 0.21 fold expression in
heterozygous +/rmd muscles and 14-fold higher expression of Chkb in the Tg-WT mice (Fig
2C). Body weights of Tg-+/rmd mice were not significantly different from Tg-rmd and +/rmd,
indicating absence of a detrimental effect of Chkb overexpression (Fig 2D). It was also observed
that Tg-rmd and Tg-WT mice were physically indistinguishable from each other (Fig 2E).
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FIG 2. Chkb-transgene construct, related phenotype and expression levels in mice.
(A) demonstrates the Chkb transgene construct with a functional copy of Chkb cDNA
inserted downstream of a complete exon 1 and partial exon 2 structure followed by a
SV40Poly A site downstream of the Chkb cDNA. (B) shows a WT (+/+), Tg-rmd and rmd
(rmd/rmd) mouse from top to bottom with the Tg-rmd mouse being physically comparable
to the WT. Chkb gene expression in muscle is 18-fold higher in Tg-rmd and 14-fold higher
in Tg-WT mice as seen from real time PCR analysis, whereas expression in rmd mice was
not detectable and that in +/rmd mice was 0.21 times higher than in rmd mice (C). Tg-rmd,
+/rmd (unaffected littermates) and Tg+/rmd mice do not show significant differences in
their body weights when measured starting at 3 weeks of age (post wean) (D). The Tg-rmd
and Tg-WT mice are physically indistinguishable from each other (E). N=4
mice/sex/genotype.

To determine if our transgene functionally rescued motor performance, we tested for
rescue of motor performance in 8-10 week old Tg-rmd mice (n=10 mice/sex/genotype) using
behavioral assays including open field, rotarod, grip strength and the Erasmus ladder tests.
Mutant rmd mice showed megamitochondria with decreased mitochondrial numbers and
increased mitochondrial areas at 2 weeks of age (Supplementary Fig 3 A-D) accompanied by
significant motor deficits at 4-5 weeks of age, rendering them unsuitable for testing at 8-10
weeks as with the Tg-rmd mice. (Supplementary Fig 3 E-K).
The open field test was used to assess basic locomotor function (ambulation) (Paumier,
Rizzo, 2013, Bailey, Crawley, 2009). Tg-rmd male and female mice travelled an equal distance
(Fig 3 A-B) and showed similar vertical activity (Fig 3 C-D) as the control male and female
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mice, suggesting normal ambulation and rearing ability.
The accelerating rotarod is a forced performance test used to examine motor impairments
(Paumier et al., 2013)(van der Vaart, van Woerden, Elgersma, de Zeeuw, & Schonewille, 2011).
When tested for their ability to perform on the rotarod, our Tg-rmd mice were not different from
their control littermates, indicating normal motor endurance and performance levels (Fig 3 E-F).
We tested muscle function using a grip strength assay (Brooks, Simon, 2009). Grip
strength of fore paws and all paws were tested and normalized to body weight in order to gauge
the severity of the dystrophy phenotype. The Tg-rmd males and females showed a grip strength
similar to their control littermates indicating normal fore paw and all paw grip strength (Fig 3 GH).
Fine motor coordination and balance were tested using the Erasmus ladder, which
specifically tests cerebellar motor coordination related to the precision and accurate timing of
movement. The Erasmus ladder assay is sensitive to perturbations or disorders in fine movement,
equilibrium, posture and fine learning and can distinguish between motor learning and motor
coordination problems more accurately than other tests, making it a suitable device to test for
subtle motor coordination disabilities in rodents (van der Vaart et al., 2011)(M. F. Vinueza Veloz
et al., 2012)(Mara Fernanda Vinueza Veloz et al., 2014). A greater percentage of missteps and
back steps on the ladder rungs indicate motor balance and coordination deficiencies. Our Tg-rmd
males and females were not significantly different from the controls in percent backsteps and
percent missteps during the assay. Both, control and Tg-rmd mice had a similar reaction to the
addition of a sound cue on day 5 and showed similar increases (but not significantly different
from each other) in the percent back steps in both male and female mice (Fig 3 I-L).
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FIG 3. Test of muscle strength in Tg-rmd mice. Open field results for spontaneous
locomotion, suggests normal ambulation in the Tg-rmd mice, with distance travelled not
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(p=0.66) (A)(B). Tg-rmd male (p=0.31) and female (p=0.67) mice show no significant
differences in their vertical activity (C)(D). Latency to fall from 3 individual trials on the
rotarod assay show normal motor strength in the Tg-rmd male (p=0.41) and female
(p=0.74) mice (E)(F). Grip strength assay results suggests normal forepaw and all paw
normalized grip strength, respectively, in the Tg-rmd mice compared to the unaffected
controls tested. Where males showed a p=0.07 and females showed p=0.25 in forepaw grip
strength (G), whereas males showed a p=0.37 and females, a p=0.09 in all paw grip strength
(H). Erasmus assay for fine motor balance and co-ordination in Tg-rmd mice shows no
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Mitochondrial area measurements (n=4 mice/sex/genotype) from sections of the
gastrocnemius muscle analyzed by transmission electron microscopy showed that while rmd
mutant mice had mitochondria that averaged 5 times larger than those of wild type mice (p < 104

), mitochondrial size was restored to normal in Tg-rmd mice (p = 0.1355; Fig 4 A-D). This can

also be seen in the frequency distribution of mitochondrial areas where Tg-rmd mice restore the
percentage of small mitochondria while reducing the frequency of mitochondria exceeding 1
nm2, whereas the rmd mice showed few mitochondria as large as 6 nm2 (Fig 4E). Mitochondrial
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numbers are reduced by half in the affected rmd mice whereas, Tg-rmd mice show similar
mitochondrial numbers to their wild type littermates (Fig 4F). Therefore, restoration of Chkb
gene expression in skeletal muscle provides a cell-type specific rescue of Chkb expression and
rescues the mutant rmd phenotype.
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Together, these results indicate restoration of muscle strength and coordination in Tg-rmd
mice and hence a prevention of the rmd disease phenotype. No aberrant mouse behavior or
deaths were observed in any transgenic mice indicating an absence of toxic effects from
overexpression of the Chkb transgene. However, in order to test this in a more thorough manner,
we examined wild-type C57BL/6J mice carrying the Ttn-Chkb transgene (Tg-WT) and assessed
levels of Chkb expression and motor strength.
The Tg-WT mice were tested on the open field, rotarod and grip strength assays to
confirm absence of any detrimental effects of transgene overexpression on motor performance.
Open field tests performed on n=10 mice/sex/genotype, showed distance travelled by TgWT is similar to that of WT mice (Fig 5 A-B). The Tg-WT male and female mice showed a
similar latency to fall compared to the WT controls on the rotarod assay (Fig 5 C-D). In the grip
strength assay, the Tg-WT males are not significantly different from WT male controls in their
fore paw and all paw grip strength normalized to body weight. While the Tg-WT females did not
show any difference in their fore paw grip strength, they showed a slightly significant increase in
their all paw grip strength compared to WT controls (p=0.01) (Fig 5 E-F). These results confirm
that overexpression of Chkb gene does not result in any immediate detrimental effects in mice.
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effects of over-expression of Chkb transgene in a WT mouse, it was observed that Tg-WT
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mice did not show significant differences in locomotor activity in both male (p=0.45) and
female (p=0.10) groups when compared to WT mice on the open field assay (A)(B).
Latency to fall on the rotarod assay in males, p=0.25, (C) and females, p=0.25 (D) and fore
paw and all paw grip strength in male (p=0.13 and p=0.39) (E) Tg-WT mice were not
significantly different compared to WT controls. The female Tg-WT mice did not show
difference in fore paw grip strength (p=0.86) but showed slight difference in all paw grip
strength (p=0.01), when compared to WT controls. These tests indicate lack of immediate
toxic effects in transgene expression. N=10 mice/sex/genotype aged 8-10 weeks. Error bars
represent mean and SD.
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Dietary circumvention of defects in Kennedy pathway fail to rescue rmd phenotype:
While the restoration of Chkb gene expression with a muscle-specific transgene was capable of
preventing the onset and progression of dystrophic symptoms, we also sought to test whether we
could bypass the biochemical defect by providing a downstream metabolic product of the
Kennedy pathway via dietary supplementation. Previous studies have shown that intravenous
injections of CDP-choline, a metabolite in the Kennedy pathway that is downstream of the action
of CHKB, can help to prevent acute muscle damage in rmd mutant mice (Wu et al., 2009). We
tested whether dietary supplementation with CDP-choline could also decrease dystrophy in the
absence of Chkb. For the study, 500mg/kg/day of CDP-choline was provided in the diet for a
period of 3 months beginning at 3 weeks of age (Secades JJ, 1995)(Agut J., 1983)(Bachmanov,
Reed, Beauchamp, & Tordoff, 2002). Mutant rmd mice (n=8 mice/sex) on dietary
supplementation were weighed daily for changes in growth rate and effects of supplementation
of the overt dystrophic symptoms compared to their non-supplemented controls (n=4 mice/sex)
and supplemented WT mice (n=4 mice/sex). However, no improvements were observed in the
growth rate or behavior of treated mice over the study duration (Supplemental Fig 1 A-B). At
the end of this study, 2 mice/sex/genotype were randomly selected to perform mass spectrometry
analysis for components of the Kennedy pathway in muscle tissues of the treated mice and body
weights were analyzed. Mass spectrometry analyses showed no significant differences in the
levels of CDP-choline in the gastrocnemius muscle between the control and test groups
(Supplemental Fig1C). These results indicate that a dietary supplementation of CDP-choline
does not lead to improvement of muscular dystrophy in adult rmd mice.
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Introduction of Chkb post-disease onset improves dystrophy phenotype in rmd mice:
The mutant rmd disease phenotype is observed as early as 2 weeks of age, with the mice showing
giant mitochondria with decreased mitochondrial numbers and decreased muscle strength
(Supplemental fig 2 A-D). Hence, in order to test the effects of up-regulation of Chkb expression
in post-disease onset adult skeletal muscle, we performed intramuscular injections of rmd mutant
mice at 3 weeks of age with an adeno-associated viral vector-6 carrying a 3X Flag-Tagged
functional copy of the mouse Chkb cDNA and a self-cleaving p2A peptide-EGFP reporter gene
into the gastrocnemius muscle. Each rmd mouse served as its own control with the left leg being
injected with the AAV vector and the right leg being sham injected with an equal volume of
saline. Seven weeks post-injection, their gastrocnemius muscles were analyzed for changes in
muscle weight, fiber area and percent of centralized nuclei. Gross observation showed an
increase in muscle size in the AAV-injected muscle (Fig 6A). In vivo fluorescence images of
injected rmd and unaffected WT mice showed that EGFP fluorescence was localized to the site of
injection indicating localized muscle transduction. No EGFP fluorescence was detected in the
saline injected leg (Fig 6B). Gross H&E-stained histological sections (Supplemental Fig 3 A-B)
revealed a significant improvement in muscle fiber morphology in the AAV-Chkb injected
muscles compared with the saline injected muscles. Montage images of the medial and lateral
gastrocnemius muscle show a rescue of muscle fiber morphology in AAV-Chkb injected muscles
(Fig 6C) when compared to the saline injected muscle (Fig 6D). We describe this as a partial
rescue with the majority of muscle fibers in the injected rmd leg having cross-sectional fiber
areas comparable to that of unaffected muscle fibers and show no centralized nuclei. However,
there remain a percentage of muscle fibers with significantly smaller cross-sectional areas
comparable to those of rmd mutant muscle and that show centralized nuclei. The partial nature of
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rescue can be attributed to the fact that not all fibers may have been transduced when injected at
3 weeks of age. The AAV-injected muscles of rmd mice showed a significant increase in muscle
weight in both males (p=0.004) and females(p=0.006) compared to the saline injected muscles,
whereas, the AAV-injected muscles of the unaffected WT mice showed no difference in muscle
weight (p>0.99 in males and p=0.65 in females) suggesting that overexpression of CHKB
rescues muscle in dystrophic mice but does not induce muscle hypertrophy in control mice (Fig 7
A-B). AAV-injected rmd muscles showed a reduced percent of centralized nuclei compared to
saline injected muscles (p=0.001 in males and p=0.06 in females), while those from AAVinjected WT muscles did not show any significant differences when compared to the saline
injected contralateral muscles (p=0.35 and 0.29 in males and females respectively) (Fig 7 C-D),
reflective of the specificity of rescue of the disease phenotype without alteration of normal
muscle. Analysis of cross-sectional myofiber areas showed a significant increase (p=0.0001) in
the average fiber areas of AAV-Chkb injected rmd muscles. Classifying fiber areas in 4 quartiles
into small (S=0-307 nm2), medium 1 (M1=307.01-795 nm2), medium (M2= 795.01-1391 nm2)
and large (L=1391.01-14093 nm2) showed a significant increase in the percent of M1, M2 and L
fiber sizes and a significant decrease in the percent of S fiber sizes in the AAV-injected rmd
muscle compared with the saline injected muscle (Fig 7 E-F).
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FIG 6. Effects of AAV-Chkb injection on rmd muscle phenotype. Gross anatomical
observations show comparatively larger size of the injected muscle compared to saline
injected muscle (A). In vitro fluorescence imaging show fluorescence localized to the
injected muscle and no fluorescence in the saline injected muscle (B). Cross sections of
whole gastrocnemius muscle at 1.25X on the nanozoomer show comparatively larger size of
the injected muscle (C) compared to the saline injected muscle (D). Inset figures at 20X
magnification represent partial restoration of muscle fiber in AAV-injected muscles as
opposed to saline injected muscle.

26

Males

C

Males

E

Fiber area nm2

le

le

us
c
m

us
c
te
d

m
ed

fe
c

ct
te
d
in
je
c

Sa

lin
e

in
je
c
hk
b

A

AV
-C

un
af

un
af
fe
d

te
in
je
c

te

in
je
c
hk
b

Sa
lin
e

AV
-C
A

le

le

us
c

m

d

d

rm
d

rm
te
d

te
fe
c

Sa

A

75

20

ns
10
0

L
M2
M1
S

le
m
ed

m

Sham injected rmd

Condition

AAV-Chkb
rmd muscle

Injected unaffected

Saline- rmd
muscle

Sham injected unaffected

Salineunaffected
muscle

0

AAV-Chkb
unaffected
muscle

lin
eun
af

fe

ct

d

ed

te
Sa

hk
bun
af

fe
c

ct
fe

us
c

le
us
c

us
c
m

us
c
m
d
m
Sa

A

AV
-C

lin
eun
af

hk
br
A

Area
50

25

fe
un
af

P
e
r
c
e
n
t

Percent

30

le

ct

**

40

le

Percent Centralized Nuclei

le

le

us
c

us
c

m
ed

m
ed
ct
fe

lin
e-

Sa

AV
-C

hk
bun
af

Sa

lin
e-

m

rm

d

d

m

m

us
c

us
c

le

le

0

A

m

us
c

le

le

us
c
d

m
d
fe
c

te

lin
erm
Sa

m

le

us
c

us
c

m
d

m
d
m
hk
br

A

AV
-C

AV
-C

Sa

A

AV
-C

hk
bun
af

us
c
m
d

fe
ct
ed
lin
m
eus
un
cl
af
e
fe
ct
ed
m
us
cl
e

le
us
c

fe
m

m
d

in
le

m
hk
br
AV
-C

rm

A

lin
eSa
50

hk
br

500

100

*

A

***
1000

F

Females

ns

100

1500

0

D

Females
150

AV
-C

ns

0

al
es

0

10

le

50

20

us
c

**
100

un
af

150

ns
2000

lin
e-

200

Muscle weights (mg)

30

Percent Centralized Nuclei

ns

B

Fiber area - Male and Female

**

AV
-C

Muscle weights (mg)

250

hk
bun
af

A

Injected rmd

FIG 7. Effects of AAV-Chkb injections on rmd muscle weights, centralized nuclei and fiber
size. AAV-Chkb injected gastrocnemius muscles in males (A) and females (B) show
significantly higher and restored muscle weights compared to sham injected muscles,
whereas there is no difference in the AAV-Chkb and sham injected gastrocnemius muscles
of unaffected mice. Percent of centralized nuclei, an indicator of poor muscle health, was
observed to be significantly reduced in AAV-Chkb injected rmd muscles compared to the
sham injected muscles in both males (C) and females (D). Injected unaffected muscles did
not show any significant differences when compared to sham injected unaffected muscles in
both males and females (C-D). Injected rmd muscles show a significant ( p=0.0001) increase
in average fiber areas, in males and females, compared to sham injected rmd muscle with
a significant increase in percentage of large (L) and medium (M1, M2) fibers and a
decrease in the percent of small (S) muscle fibers (E-F). N= 8 mice/sex/genotype. Mice were
injected at 3 weeks of age and their gastrocnemius muscles harvested at 7 weeks of age.
Error bars represent mean and SD.
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Chka can compensate for lack of Chkb in rmd mutant mice. The normal developmental loss
of Chka gene expression in mouse caudal muscles during postnatal muscle differentiation makes
skeletal muscles of the hindlimb particularly susceptible to disease in the case of Chkb gene
mutations in mice. In order to test the hypothesis that the paralogous CHKA protein can
functionally compensate for CHKB deficiency in rmd mice, we injected rmd muscles with an
AAV vector expressing a human CHKA cDNA. The AAV-injected muscles were observed to be
larger than the saline injected muscles seven weeks post-injection (Supplemental Fig 3 C). In
vivo fluorescence imaging of rmd mice showed that EGFP florescence was localized to the site
of injection whereas the saline injected site did not display any fluorescence (Supplemental Fig 3
D). Like the Chkb gene therapy experiment, H&E staining of AAV injected muscles showed
major regions of restored muscle structure (Supplemental Fig 3 E-F). Montage images stained
with Gordon and Sweet’s to highlight the circumference of each myofiber showed significant
regions with normal morphology and regions of partial rescue in the AAV-CHKA injected rmd
muscles (Supplemental Fig 4 E-F). The AAV-injected muscles of rmd mice weighed
significantly more than the saline-injected contralateral muscles with a p=0.008 and p=0.006 in
males and females respectively. The difference in muscle weights between the AAV and sham
injected WT control mice was not significant (p=0.31 in both males and females) (Fig 8 A-B).
AAV-injected rmd muscles showed a decrease in the percent of centralized nuclei in comparison
to saline injected rmd muscle (p=0.16 and p=0.008 in males and females respectively), while the
AAV-injected control muscles were not significantly different from the saline-injected control
muscles (p=0.06 and p=0.16 in males and females respectively) (Fig 8 C-D). Similar to our
AAV-Chkb injections, treatment with the AAV-CHKA virus rescues the disease phenotype in
dystrophic muscles without inducing hypertrophy of normal muscle in WT mice. AAV-injected
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muscles showed a significant increase (p<0.0001) in average muscle fiber area in males and
females. Fiber areas were classified into 4 quartiles, as in case of Chkb injections, into small
(S=0-209 nm2), medium (M1=209.01-630 nm2), medium (M2=630.01-1159 nm2) and large
(L=1159.01-8387 nm2). AAV-injected rmd muscles showed a significant increase in the percent
of M1, M2 and L fiber sizes and a significant decrease in the percent of S fiber sizes (Fig 8 E-F).
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FIG 8. Effects of AAV-Chka injections on rmd muscle weights, centralized nuclei and fiber
size. AAV-Chka injected gastrocnemius muscles in males (A) and females (B) show
significantly higher and restored muscle weights compared to sham injected muscles,
whereas there is no difference in the AAV-Chkb and sham injected gastrocnemius muscles
of unaffected mice. Percent of centralized nuclei was observed to be significantly reduced in
AAV-Chka injected rmd muscles compared to the sham injected muscles in both males (C)
and females (D). Injected unaffected muscles did not show any significant differences when
compared to sham injected unaffected muscles in both males and females (C-D). Injected
rmd muscles show a significant ( p<0.0001) increase in average fiber areas, in males and
females, compared to sham injected rmd muscle with a significant increase in percentage
of large (L) and medium (M1, M2) fibers and a decrease in the percent of small (S) muscle
fibers (E-F). N= 8 mice/sex/genotype. Mice were injected at 3 weeks of age and their
gastrocnemius muscles harvested at 7 weeks of age. Error bars represent mean and SD.
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Discussion:
The discovery and characterization of the spontaneous rmd mutant mouse led to the discovery of
CHKB as the gene underlying MDCMC (Sher et al., 2006b)(Mitsuhashi, Hatakeyama, et al.,
2011), establishing the validity of the rmd mouse as a model of the human disease and opening
up avenues for mechanistic and preclinical studies. MDCMC is caused by recessive loss of
function mutations in the choline kinase beta gene. We have shown that the ubiquitous loss of
Chkb in rmd mutant mice leads to a cell and tissue-specific disease which can be restored by
upregulating expression of Chkb in skeletal muscle tissues only, indicating that regeneration of
skeletal muscles in a Chkb-deficient environment is cell-autonomous. Intramuscular AAV
injections of Chkb and Chka gene also help restore muscle morphology in rmd mutant mice,
while dietary supplementation of Kennedy pathway intermediates does not have a regenerative
or rescue effect.
Gene replacement of Chkb by transgenesis or by AAV6 delivery rescues the muscular
dystrophy phenotype of the rmd mouse. Introduction of a functional copy of the Chkb transgene
under a muscle-specific promoter prevented disease onset, with the Tg-rmd mice showing
normal mitochondrial dimensions and muscle strength. This indicates that although the Chkb
gene is ubiquitously expressed, the enzyme deficiency results in a muscle-specific defect in
phosphatidylcholine biosynthesis that can only be rescued by a cell-autonomous increase of
CHKB activity within muscle cells themselves. Overexpression of the Chkb gene up to a 14-fold
magnitude does not cause a negative impact on the Tg-WT animals, with mice showing
behavioral and muscle strength phenotypes comparable to their non-transgenic littermates.
Further, introduction of the Chkb gene using AAV6 post-disease onset in young adult rmd mice
can help reverse the degenerative muscle disease. Intramuscular AAV6 vector injections
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containing a functional copy of Chkb gene in adult skeletal muscle resulted in improved muscle
regeneration capacity and subsequent increased muscle weights and fiber areas with a decreased
number of centralized nuclei compared to untreated rmd muscles (Hollinger & Chamberlain,
2015)(Zincarelli, Soltys, Rengo, & Rabinowitz, 2008)(Ramos, Chamberlain, & Muscular, 2015).
A detailed analysis of fiber areas shows an increase in the percent of large and medium sized
fibers in AAV injected muscles with a significant decrease in the percent of small sized fibers.
The presence of different fiber sizes pre and post AAV-Chkb injections illustrate the partial
nature of fiber rescue. It can be inferred that the transduced rmd muscle fibers regenerated to a
healthier phenotype whereas, the rmd muscle fibers that were already atrophied and wasted or
that were not transduced remained unhealthy, showing a dystrophic phenotype. These results
suggest that replacing Chkb gene, post disease-onset and in adult mice helps reverse muscular
dystrophy by increasing muscle regeneration in a cell-autonomous manner in dystrophic rmd
mice. Injecting and thus upregulating Chkb expression in unaffected muscles did not have any
detrimental effects as indicated by lack of hypertrophy in AAV-Chkb injected skeletal muscles,
indicating that upregulation of the CHKB gene in MDCMC patients via AAV mediated gene
therapy can be a possible therapeutic measure. We have also shown that up-regulation of CHKA
by localized AAV-CHKA injections helps to restore muscle regeneration and alleviate the
dystrophic phenotype in rmd muscles, similar to AAV-Chkb injections, making this another
potential therapy for MDCMC.
Biochemical studies suggest that choline kinase alpha and beta can function either
as homodimers or heterodimers in the phosphorylation of choline to phosphocholine for the
production of phosphatidylcholine (Aoyama et al., 2004). In rmd mice, total choline kinase
activity in the hindlimbs is absent whereas in the forelimbs, choline kinase activity is attenuated
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by only 50% (Wu et al., 2010a). These results led to the hypothesis that there must be an agedependent reliance on the activity of CHKB in WT hindlimb skeletal muscles of mice as Chka
gene expression decreases. The partial retention of choline kinase activity in the forelimbs of
adult rmd mice (due to residual Chka expression) provides a possible explanation for the
decreased severity of disease in forelimb muscles versus the much more severe and progressive
dystrophy in hindlimb muscles. This led us to test the possibility that CHKA can functionally
compensate for CHKB deficiency in the severely affected hindlimb muscles of the rmd mutant
mouse. The mechanism by which the expression of Chka shuts down in adult mouse skeletal
muscles is still unclear. A study of CHKA expression in human skeletal muscle over time has not
been tested, however, GTEx expression data across 53 adult tissues shows that CHKA transcript
levels are the lowest in adult skeletal muscles (GETx Portal Version V7). Our data indicated that
increasing the expression of CHKA in post-disease onset, adult skeletal muscles results in
improved muscle regeneration, increased muscle weights and fiber areas and a decrease in the
percent of centralized nuclei with no immediate observable toxic effects. This suggests that even
though CHKA expression is normally shut down in adult skeletal muscles, upregulation of its
expression can compensate for lack of CHKB activity.
Increase expression of choline kinase alpha, but not beta, has been implicated in
tumorigenesis, with CHKA overexpression detected in 40-60% of human tumors (Chang, Few,
Konrad, & See Too, 2016). Transfecting human (Hek293T) cells with Chka resulted in
anchorage independent growth activity similar to that demonstrated by Rho-A activation
(Ramírez De Molina et al., 2005). It can be inferred that, CHKA upregulation via AAV injections
can potentially cause non-cancer cells to take on a cancerous phenotype, while siRNA
downregulation can lead to death of cancer cells. Immediate evidence (7 weeks post-injection)
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for this was not found in our experiments of localized intramuscular injections of CHKA in rmd
skeletal muscles. CHKA injected mice will need to be aged and studied for potential tumorigenic
effects of gene upregulation in order to determine whether the association between CHKA and
cancer is directly causative of disease or whether it is instead a biomarker of the cancerous state.
Chkb deficiency causes muscular dystrophy in a rostral to caudal gradient in mice as
Chka expression is shut down in caudal adult skeletal muscles. One might expect that there is a
functional reason for the observed decrease in normal Chka gene expression in adult skeletal
muscles, however our data suggests that overexpression of CHKA via an AAV gene therapy
approach is not deleterious in skeletal muscles. In the CHKB-deficient condition, CHKA can
compensate for the lack of choline kinase beta to form functional a-a homodimers for the
phosphorylation of choline to phosphocholine in skeletal muscles. Our results support that both
the upregulation of either CHKB or CHKA can be used as a potential therapy for the rescue of
MDCMC symptoms. As gene therapy may not be appropriate for all patients, strategies to
upregulate the endogenous CHKA locus might also prove effective for the alleviation of
MDCMC symptoms. Interestingly, the upregulation of CHKB or CHKA also reduces the
presence of megamitochondria, indicating that the two phenotypes are related and cannot be
rescued independent of each other. Megamitochondria are thought to result in a disruption of
normal myofiber structure, with altered cellular architecture including disordered sarcomeric and
muscle triad structures that are necessary for the orderly distribution of energy-producing
mitochondria. Whether the generation of megamitochondria in skeletal muscle directly causes
the muscular dystrophy or is just a biomarker of the disease remains to be tested.
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Materials and Methods
Mouse colonies: All mice were bred and maintained at the Jackson Laboratory following
procedures and protocols approved by our institutional animal care and use committee (IACUC).
For breeding, mice were kept in humidity and temperature controlled rooms with a 12:12
dark:light cycle. They were given an NIH-mouse diet with 6% fat (PMI Feeds, Inc., St. Louis,
MO) ad libitum with free access to water (HCl-acidified, pH 2.8–3.2). For all motor and
behavioral tests, the mice were moved to a separate room and singly housed where they were
maintained under IACUC approved conditions until completion of the test procedures. In this
facility, the mice were kept on a 4% extruded grain diet and were provided with clean acid water
unless mentioned otherwise.
Generation of transgenic (rescue) mouse: Expression of Chkb transgene in transgenic mice,
for the generation of rescues was achieved by using the titin (Ttn) promoter to express the Chkb
cDNA transgene specifically in skeletal and cardiac muscles (Maddatu et al., 2005a). This
promoter reproduces the endogenous pattern of titin expression in muscles prior to the onset of
the rmd disease symptoms. The Ttn promoter includes 3.5 kb of sequence upstream of the noncoding Ttn exon 1, the entire 2.1 kb of intron 1 and exon 2 is truncated just before the start
codon. The inclusion of an intron in the construct is beneficial for proper long term expression in
transgenic mice and to take advantage of any possible control elements that might be located in
the first intron. The polyadenylation signal is a 200 bp fragment derived from the SV40 viral
genome that we have successfully used in numerous transgenic lines. A 1589bp Chkb cDNA
fragment, including 234bp upstream from the exon 1 ATG start codon (Ch15 reverse strand,
89,429,834bp, Ensembl GRCm38) to 145 bp downstream from the exon 11 TGA stop codon
(89,426,584bp) was PCR cloned and blunt-ligated into the Ttn plasmid backbone immediately
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after the truncated exon 2. The completed pTtn-Chkb constructs were injected into fertilized
C57BL/6J eggs by the microinjection. Transgenic founders were bred to C57BL/6J mice to
generate a stable colony and maintain the transgene on an inbred background. Transgenic mice
were identified through PCR of tail DNA with a forward primer in the 3’ end of the TTN
promotor sequences, TTN100F (5’-TCTCCACCAAGAAGACGCTG-3’) together with a reverse
primer in the 3rd exon of Chkb, Chkb-e3R (5’-CTTTCTAATACCAAGGAGTCTACACC-3’).

Mitochondrial area
Specimen preparation: For Transmission Electron (TE) microscopy, 4 mice per genotype (rmd,
WT and Tg-rmd) were used to analyze mitochondrial structure. The medial and lateral
gastrocnemius muscle were isolated and fixed in a solution of 2% paraformaldehyde, 2%
glutaraldehyde, in 0.1 M cacodylate buffer (pH 7.2) at 4°C overnight. Tissues were then washed,
dehydrated in graded series of ethanol and processed for 812 resin embedding. Samples were
then cured at 70°C for 48 hours followed by thin sectioning (90nm) with a Leica EM UC6
ultramicrotome (Leica Microsystems, Buffalo Grove, IL) on a diamond knife. The sections were
then placed on 300 mesh copper grids and stained using 2% uranyl acetate and Reynolds lead
citrate. Samples were evaluated at 80 kV using a JEOL JM-1230 transmission electron
microscope (JEOL, Tokyo, Japan) and images collected with an AMT 2K digital camera
(Advanced Microscopy Techniques, Woburn, MA).
Mitochondrial area calculations: 10 pictures per sample (n=4) were taken using the TE
microscope. Mitochondrial areas were measured using FiJi and analysis of variance calulations
were performed on Prism software (version 7.0c for Mac OS X).
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Behavioral and motor assays: Adult mice (n=10 per sex, per genotype) were put through a
battery of behavioral tests for motor function. The tester was blinded for the duration of the
entire battery of assays. The time of the day at which each test was performed was kept constant
for each assay performed. The mice were allowed a minimum resting period of 2 days between
every test. All equipment was sprayed down and wiped with 70% ethanol before and in between
testing mice. The test animals were habituated for 60 mins in the testing room before each test.
The order of testing was as follows; open filed, rotarod, grip strength and Erasmus ladder.
Open field test: Post habituation in testing room, mice were individually placed in standard
Verasamax chambers, under standard lighting conditions of ~500 lux and with standard
background noise levels of about 62 -65 dB. The mice were tested for 60 mins with data
collection in 5 min bins. Analysis was performed for total distance travelled (cm), (Paumier et
al., 2013)(Seibenhener & Wooten, 2015)(Asinof et al., 2015)(Crawley, 2000)(Tatem et al.,
2014)(Sukoff Rizzo et al., 2018).
Rotarod test: The Ugo Basile rotarod was used to analyze motor co-ordination and balance in
mice. The rotarod drum was steadily accelerated from 4 to 40 rpm over a 300 sec duration. Each
animal was put through 3 consecutive trials and the average latency to fall was recorded. Mean
of combined latency to fall of the entire group was also calculated (Paumier et al., 2013)(van der
Vaart et al., 2011).
Grip strength test: Animals were individually tested using the force gauge by BIOSEB. Each
animal was tested for three forepaw trials and three all paw trials (6 total trials). A force
transducer is used to measure maximum force generated which is then normalized to body
weight and analyzed analyzed using the BIO-CIS software (Brooks & Dunnett, 2009)(van der
Vaart et al., 2011).
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Erasmus Ladder: Fully automated Erasmus ladder was used to study locomotion and motor
coordination in mice. Noldus equipment with software Version 1.1 as described by R Van Der
Giessen, et al, 2008 and Vinueza et al, 2012, were used for the testing procedure. Each animal
was run through 42 trials per day for 5 consecutive days. For all the trials there was perturbation
but no tone cue used. Tone cue was added to the trials on day 5 of the testing. (Van Der Giessen
et al., 2008)(M. F. Vinueza Veloz et al., 2012). During data acquisition, the mice were kept in
the pexiglass chamber of the goal box. Data for percent missed steps and percent backsteps, were
recorded and later analyzed (Mara Fernanda Vinueza Veloz et al., 2014).

CDP-choline diet supplementation: For this study, 4 WT mice/sex and 8 rmd mice/sex were
provided with CDP-choline supplemented 76A lab diet gel from Clear H2O and 4 rmd mice/sex
were used as controls and were fed plain diet gel. Same sex mice were housed in doublets in
each side of a duplex mouse cage. 87.5mg of CDP-choline was mixed in 56gms of standard 76A
lab diet gel cups. On an average a mouse eats 8gms of diet gel per day giving them a dose of
500mg/Kg/day. Diet gel cups were changed 3 times a week (Bachmanov et al., 2002). The WT
mice were administered diet gel cups spiked with CDP-choline to assess to possibility of toxic
effects due to increased consumption of CDP-choline. 8 rmd mice/sex were administered CDPcholine spiked diet gel cups, these are referred to as Test mice and the remaining 4 rmd mice/sex
were administered standard diet gel cups with no CDP-choline added, these are referred to as
control mice. The total length of this study was 3 months. Mice were weighed and assessed for
general health every week (Wu et al., 2012)(Secades JJ, 1995)(Wurtman, Regan, Ulus, & Yu,
2000).
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Adeno-Associated Viral vector design: Adeno-Associated Viral vector design: An AAV
subtype 6 was selected as it shows higher gene expression and tropism in skeletal muscles
(Zincarelli et al., 2008)(Hollinger & Chamberlain, 2015). AAV vector plasmid AAV-Chkb was
derived from AAV-CAG-GFP plasmid (Addgene #28014). This plasmid contains mouse Chkb
cDNA tagged by a 3X Flag Tag (5GACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGACTACAAGGATGA
CGATGACAAG-3’) at the 5’ end in order to distinguish transduced Chkb expression from
endogenous expression, all under the control of a CAG (CMV early enhancer/chicken beta actin)
promoter. The plasmid also contains EGFP as a gene expression reporter protein, the expression
of which is driven by the CAG promoter through P2A ribosomal skipping sequence downstream
of the Chkb coding sequence (Y. Wang, Wang, Wang, Zhao, & Xia, 2015). Recombinant AAV6
vectors were produced by triple transfection of HEK293T/17 cells with Chkb plasmid DNA,
pAAV2/6 packaging plasmid, and pAd delta F6 helper plasmid (Penn Vector Core) using linear
polyethylenimine (PEI). Transfected cells were incubated at 37°C, 5% CO2 in DMEM
supplemented with 2.5% fetal bovine serum. Three days after transfection, the crude vector
fraction was obtained by combining the precipitated products from culture medium with final 8%
polyethylene glycol and the cell extracts lysed by repeated freeze–thaw cycles. The crude vectors
were then purified by iodixanol density-gradient ultracentrifugation. Purified AAV6 vector was
dialyzed against 1× PBS with 5% sorbitol. Viral titer was measured using real time PCR with
primers for the ITR region (5'-GGAACCCCTAGTGATGGAGTT-3' and 5'CGGCCTCAGTGAGCGA-3'). A final volume of 300µl with a concentration of 1.84 X 1013
vg/ml was obtained for AAV-Chkb injections and 150µl of 2 X 1014 vg/ml of AAV-Chka.

39

Transduction of muscle fibers and tissue processing: The left gastrocnemius muscle of 3
week old rmd mice and unaffected controls were injected locally with 2 X 1010vg of AAV vector
solution in 25µl PBS. The right gastrocnemius muscle was treated as control and injected with
25µl of sterile PBS solution only (Lu et al., 2003)(Liu, Yue, Harper, Grange, & Jeffrey, 2008).
The injected animals were aged on shelf for 7 weeks post-injection and the gastrocnemius
muscles were harvested at 10 weeks of age and fixed in 10% neutral buffered formalin for 24hrs
before embedding in paraffin.

Muscle fiber staining:
Gordon and Sweets stain for reticular fibers: Injected gastrocnemius muscles were harvested 7
weeks post injection and fixed in 10% Neutral buffered Formalin (NBF). Samples were then
oxidized in 1% potassium permanganate solution, bleached in oxalic acid, sensitized in 2.5%
ferric ammonium sulfate and impregnated with ammoniacal silver solution. Following a rinse
and a 2 min fix in formalin, the samples are toned in 0.2% gold chloride solution and washed
with 5% sodium thiosulphate. Samples are rinsed, dehydrated and clear mounted for microscopy
analysis.
Hematoxylin and Eosin staining: Injected muscle fibers were fixed in 10% NBF and embedded.
Post embedding, the samples were processed in a Leica automated stainer by Histology core
services at the Jackson Laboratory.
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Statistical analysis: All the experiments were performed at the Jackson Laboratory, Bar Harbor.
All mouse handling, testing, and analysis were performed blinded for mouse genotype. Where
appropriate, statistical significance was calculated using Student’s t-test or 2-way ANOVA with
post-hoc Bonferroni corrections unless otherwise noted. Calculations were performed using
Prism 7.0c software for Mac OS X and any significant differences (p<0.05) between test and
control strains are denoted by an asterisk symbol.
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CHAPTER 3
SIGNIFICANT DIFFERENCES IN BRAIN LIPID PROFILES DO NOT TRANSLATE
TO BEHAVIORAL DIFFERENCES IN TRANSGENIC RMD MICE.

Abstract:
Congenital muscular dystrophy with megaconial myopathy (MDCMC) is characterized
by an early onset of muscle degeneration and wasting, megamitochondria and severe cognitive
impairments. As reported earlier, we have identified a spontaneous mutant mouse- rmd, with a
1.5kb deletion in choline kinase beta gene (Chkb) that shows muscular dystrophy in a rostral to
caudal gradient and megamitochondria. The rmd mouse has been characterized for muscle
strength, function and enzyme biochemistry, all of which match the phenotype seen in MDCMC
patients. Here we tested whether the rmd mice can also be used to model the cognitive
impairments seen in MDCMC patients. We have used a muscle-specific Chkb transgene to
rescue the muscular dystrophy in rmd mutant mice in order to conduct behavioral assays for the
determination of working memory and learning in Chkb deficient conditions. Along with this, we
have also conducted a detailed MS/MSALL mass spectrometry analysis on rmd and Tg-rmd mice
in comparison to WT mice to test for differences in brain lipid profiles as has been observed in
cases of cognitive impairment. We observed that even though there are significant differences in
the lipid profiles of brain tissue from rmd and Tg-rmd mice compared to WT mice, these
changes do not translate to significant differences in behavioral analysis of the same mouse
models. Our data contributes to the characterization of cognitive impairments in a mouse model
of MDCMC and defines lipidomic changes in the brain of Chkb-deficient mice.
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Introduction:
Congenital muscular dystrophy with megaconial myopathy (MDCMC) is a rare form of
muscular dystrophy in which patients suffer from muscle wasting and have giant mitochondria.
In addition, in all reported cases of MDCMC, patients were found to have cognitive
impairments, demonstrated by an IQ lower than the general average of 90 on the Stanford-Binet
scale, speech defects and slow learning (Nishino et al., 1998)(Mitsuhashi, Ohkuma, et al., 2011).
As reported in chapter 1, we have discovered a mutant mouse (rmd) carrying a spontaneous
deletion in the Chkb gene and display an early onset progressive muscular dystrophy with
prominent megamitochondria. Mutant rmd mice show two out of three phenotypes observed in
MDCMC patients and here we determined whether rmd mice could also model the cognitive
impairments observed in the MDCMC patients, thus making it a model for all of the major
aspects in MDCMC phenotype.
Cognitive impairment in a mouse can be tested by running a battery of behavioral assays
that include tests for working and short-term memory and learning potential in the mice. These
assays require the mice to perform tasks that require a certain level of physical activity. The rmd
mice start dragging their hindlimbs at about 8 weeks of age, making this level of physical
activity near impossible for some of the tests that continue even after the mice are about 6
months of age. As a result, the rmd mice could not be used to assess cognitive impairments.
As reported in chapter 2, the Tg-rmd mice have been engineered to carry a functional copy of the
Chkb gene under the control of a skeletal muscle specific promoter-Titin, this gives them a
rescued phenotype in the skeletal muscles but a retains the CHKB-null phenotype in brain
tissues, making them a good model for the testing of cognitive impairments.
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Choline and phosphatidylcholine in normal brain development:
It has been shown that the deficiency of CDP-choline, a downstream metabolic product
of phosphorylation of choline can detrimentally affect neuronal cells and more specifically the
glial cells of the hippocampus (Zweigner et al., 2004)(Sanders & Zeisel, 2007). Lack of choline
impairs PC production, an important compound for normal brain development. Administration of
PC in mice with dementia have a neuroprotective effect and improves memory by increasing
brain acetylcholine concentration (S. Chung, et al., 1994). Single nucleotide polymorphisms
(SNPs) close to the choline kinase beta gene influences neurobehavior and can cause
susceptibility to narcolepsy (Miyagawa et al., 2008). Previous literature suggests that
deficiencies in PC production influences neuronal and neuro-behavioral phenotypes.
Choline is an essential nutrient with an average intake for men being around 600 mg/day
and that for women at about 450 mg/day. It is required to make phospholipids, especially
phosphatidylcholine, and is an important precursor for the biosynthesis of neurotransmitter
acetylcholine. Choline deficiency has been reported to cause disorders in the muscle, liver,
kidney, pancreas, developing brain and nervous system. Though choline can be synthesized de
novo, the minute quantities synthesized are not sufficient to carry out synthesis of phospholipids
and neurotransmitters and hence de novo synthesis of choline is supplemented with dietary
intake by absorption from food like organ meats, milk, eggs and peanuts. (Zeisel SH,
1992)(Sanders & Zeisel, 2007). De novo synthesis of choline is carried out by the sequential
methylation of phosphatidylethanolamine (PE) to PC, catalyzed by phosphatidylethanolamine Nmethyltransferase (PEMT) using S-adenosylmethionine (AdoMet) as a methyl-group donor.
Choline can also be generated de novo by the metabolism of PC via phospholipases.
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(Lin & Gant, 2014). Choline synthesized or absorbed from food can then pass though the
intercellular tight junctions in the brain, where it is phosphorylated to form phosphocholine and
later PC. It has been suggested that deficiency of choline and hence that of PC triggers apoptosis
in the brain (Zweigner et al., 2004). PC deficiency also results in muscular dystrophy as reported
by Sher et al. and outlined in chapter 2 (Sher et al., 2006)(Wu et al., 2009)(Zeisel, 1992). PC
cannot be transported through the blood brain barrier and hence neuronal tissue is dependent on
the synthesis of PC from transported choline.

Differences in brain lipid profile in normal and cognitively impaired humans and rodents.
The human brain is about 60% lipid, making lipids important regulators of brain function.
Studies on post mortem brain tissue from Alzheimer’s disease (AD) patients show that patients
with late onset Alzheimer’s disease (LOAD) have a distinctly different lipid profile than
unaffected humans. After free cholesterol, phospholipids form the second major lipid component
in brain with PC and phosphatidylethanolamine (PE) being the most abundant components
within the phospholipid group. It has been shown that LOAD patients show a 1.8 fold increase in
diacylglycerols (DAGs) in the prefrontal cortex (PFC) with a significant decrease of about 25%
in PE species. LOAD patients also show significant changes in sphingolipid metabolism,
monoacylglyceryl phosphate and sphingomyelins, with higher plasma levels of sphingomyelins
being predictors of slower disease progression in AD patients. The concentration of free fatty
acids in plasma was 43% lower in persons with mild cognitive impairments (MCI) and 52%
lower in AD patients. AD patients showed significant lower levels of DHA. Analysis of familial
Alzheimer’s disease (FAD) on three different transgenic mouse models showed fatty acyl long
chain remodeling with a decrease in long-chain phospholipid and long-chain sphingolipids
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balanced by increases in short and long medium length species. Selective accumulation of
medium-chain length SM was observed. Even though similar trends in changes in brain lipid
profiles were observed in humans and mice, these changes were not identical within different
regions of the brain in humans and mice exemplifying changes in different lipid species (R. B.
Chan et al., 2012)(Cunnane et al., 2012)(Wood, 2012).

Results:
rmd mutant mice have lower muscle strength than WT littermates: rmd mice begin dragging
their feet at about 8 weeks of age. Since behavioral assays for memory and learning are validated
for mice aged 8-10 weeks and require considerable physical activity like mobility in a Y-maze
and rearing activity for touchscreen, it was imperative to test for muscle strength and function in
rmd mice at an earlier age. Testing at wean age of 4 weeks was selected as the earliest time point
at which the mice can be tested and run on all the behavioral assays. The rmd mice were tested
against aged-matched WT littermates for muscle strength using open field, rotarod and grip
strength assays. The rmd males and females showed a small but significant difference from their
WT littermates (p = 0.02 and 0.04, respectively) in the total distance travelled (Fig 9 A- B).
Males and females also showed a significant difference compared to the WT in the vertical
activity with p=0.001 and 0.003, respectively (Fig 9 C-D). The rmd mice show decreased forepaw (males and females, p < 0.0001) and all-paw (males and females, p < 0.0001) grip strength
(Fig 10 A-D). In the rotarod assay, the rmd mice showed a significant latency to fall on an
average and in between trails with a P value less than 0.0001 in both males and females (Fig 11
A-B). As observed from these tests, muscle function is impaired at 4-5 weeks, making it
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impossible to use rmd mice for testing in behavioral assays like paired associates learning or
dPAL assay as these assays may continue for a period of > 3months.
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FIG 9. Measurement of open field activity in rmd mice. The rmd males and females showed a
significant difference compared to the WT in the total distance travelled (p=0.02 in males
and 0.04 in females) and in the vertically activity shown (p-0.001 in males and 0.003 in
females). N= 5 mice/sex/genotype aged 4-5 weeks. Error bars represent SD.
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FIG 10. Measurement of grip strength in rmd mice. rmd mice show significantly decreased
fore-paw and all-paw grip strength when compared to their unaffected (WT) littermates
with males and females showing p values less than 0.0001 in each of the tests (A-D),
suggesting lower grip and hence muscle strength. N= 5 mice/sex/genotype aged 4-5 weeks.
Error bars represent SD.
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A

B

FIG 11. Measurement of rotarod activity in rmd mice. rmd mice show a significant
difference from WT in latency across trials in the rotarod test with p<0.0001 (A) and a
significant difference of p<0.0001 in the average latency to fall (B) in a grouped analysis of
males and females. N= 5 mice/sex/genotype aged 4-5 weeks. Error bars represent SD.

rmd mutant mice show significant changes in lipid profile: Tissue from the cerebellum, cortex
and Mid + Hind brain region of rmd mice (N=2 mice/sex) were compared with those of WT
mice (N=2 mice/sex) in order to test for any changes in the lipid profile as observed in LOAD
and MCI patients. These mice were aged and were 56-58 weeks old at the time of brain tissue
harvest. MS/MSALL employs a sequential stepping through a user pre-defined mass range that
isolates and fragments all ions within that mass range, resulting in the collection of more than a
thousand MS/MS spectra that covers every precursor in the mass range of each cycle. MS/MSALL
is hence, more robust and efficient form of collection of mass spectra data. Lipid profiling with
MS/MSALL mass spectra suggests significant differences in the major lipid molecules like
triacylglycerols (TAGs), sphingomyelins (SMs), diacylglycerols (DAGs), monoalk(en)yl
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diacylglycerol (MADAGs) and glycerophospholipids (GPLs). Changes within species of lipid
molecules are reflected via changes in number of branches, branch length and in saturation.

A

FIG 12. PCA of TAGs in brain. Principal component analysis with Pareto scaling on
MS/MSALL Triacylglycerol (TAGs) in the brain region, showing significant differences
across genotype.

A PCA analysis of the TAG molecules in the cortex, cerebellum and mid-hind brain
region shows a significantly different clustering in rmd and WT cortex and mid-hind brain
region. The cerebellum too shows a slightly different clustering in the PCA (Fig 12). Table (1.11.3) represents the ten most significantly altered TAG molecules in the above-mentioned brain
regions. It can be seen that there alterations in long chain, unsaturated MDAG (54:9/54:10)
50

molecules which is balanced by an increase in the number of medium-chain MDAG (46:2/48:1)
molecules. The same can be found true for TAG (56:7 and 46:7) and DAG (38:5 and 36:1)
molecules.

B

FIG 13. PCA of SMs in brain. Principal component analysis with Pareto scaling on
MS/MSALL Sphingomyelins (SMs) in the brain region, showing significant differences
across genotype.

SMs in the cerebellum, cortex and mid-hind brain region of rmd and WT mice show significantly
separate clustering as observed for DAG molecules (Fig 13). Upon sorting the delta values of the
different species identified using MS/MSALL, from highest to lowest, it can be seen that ten most
significantly differing SM molecules differ in their number of side chain/ chain branches (Table
1.4 -1.6).
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C

FIG 14. PCA of DAGs in brain. Principal component analysis with Pareto scaling on
MS/MSALL diacylglycerol (DAGs) and monoalk(en)yl diacylglycerol (MADAGs) in the
brain region, showing significant differences across genotype.

DAGs analyzed in the cortex of the brain show a clear separation in the PCA for rmd and WT
mice (Fig 14). The cortex showed higher number of long and medium chain molecules with
fewer branches whereas the mid-hind brain region showed an increased number of molecules
with small to medium chain length and higher number of chain branches (Table 2.1-2.3).
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D

FIG 15. PCA of glycerophospholipids in the brain. Principal component analysis with Pareto
scaling on MS/MSALL glycerophospholipids in the brain region, showing significant
differences across genotype.

A PCA of GPLs in the brain region of rmd and WT mice showed clear separation in all three
analyzed regions with maximum separation in the mid-hind brain region (Fig 15). Major
differences were noted in the PE and phosphatidylserine (PS) molecules, with most differences
within these molecules lying in the fatty acid chains (Table 2.4-2.6).
Together with previous literature, our data suggests there is a biochemical basis for
anticipating cognitive impairments in the rmd mice, similar to the spectrum of cognitive
impairments demonstrated by MDCMC patients.
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1

2

3

Top 10 most significantly different
TAG species in cerebellum
TAG 54:6+NH4 (-FA 22:6 (NH4))
MADAG 48:7+NH4 (-FA 19:3 (NH4))
MADAG 48:0+NH4 (-FA 15:0 (NH4))
MADAG 44:5+NH4 (-FA 20:4 (NH4))
DAG 36:4+NH4 (-FA 16:0 (NH4))
MGDG 38:12+NH4 (-MGDG (NH4))
DAG 34:1+NH4 (-FA 16:1 (NH4))
MADAG 54:8+NH4 (-FA 18:1 (NH4))
MADAG 48:0+NH4 (-FA 15:0 (NH4))
MADAG 52:10+NH4 (-FA 14:1 (NH4))

p value
0.99924
0.98857
0.97427
0.9724
0.96115
0.94583
0.94491
0.94436
0.94347
0.93988

Top 10 most significantly different
TAG species in cortex
DAG 34:1+NH4 (-FA 16:1 (NH4))
MADAG 52:10+NH4 (-FA 14:0 (NH4))
MADAG 48:7+NH4 (-FA 16:0 (NH4))

p value
0.98907
0.98092
0.97418

TAG 48:8+NH4 (-FA 14:0 (NH4))
TAG 46:3+NH4 (-FA 17:2 (NH4))
TAG 54:5+NH4 (-FA 18:3 (NH4))
TAG 54:6+NH4 (-FA 16:0 (NH4))
MADAG 36:1+NH4 (-FA 16:1 (NH4))
MADAG 48:8+NH4 (-FA 12:0 (NH4))
MADAG 52:11+NH4 (-FA 14:0 (NH4))

0.96965
0.95001
0.94092
0.91744
0.91506
0.91495
0.90907

4

5

Top 10 most significantly different
TAG species in Mid-Hind brain
MADAG 50:5+NH4 (-FA 12:3 (NH4))
MGDG 38:3+NH4 (-MGDG (NH4))
MADAG 50:2+NH4 (-FA 20:1 (NH4))
MADAG 52:10+NH4 (-FA 12:1 (NH4))
MADAG 54:11+NH4 (-FA 20:4 (NH4))
MADAG 52:8+NH4 (-FA 16:1 (NH4))
MADAG 46:2+NH4 (-FA 19:2 (NH4))
TAG 54:4+NH4 (-FA 18:2 (NH4))
TAG 54:4+NH4 (-FA 18:1 (NH4))
TAG 54:6+NH4 (-FA 14:0 (NH4))

6

p-value
5.27E-08
2.01E-06
2.86E-06
4.75E-06
2.08E-05
2.62E-05
2.77E-05
2.80E-05
4.72E-05
6.35E-05

Top 10 most significantly different
SM species in cerebellum
HexCer 40:2;4 (LCB 18:1;2-2H2O,LCB 18:0;3-3H2O)

9.47E-06

HexCer 40:2;4 (LCB 18:1;2-H2O,LCB 18:0;3-2H2O)
SM 44:1;3 (SM)
SM 44:4;2 (SM)
SM 44:0;4 (SM)
SM 34:2;3 (SM)
SM 38:2;3 (SM)
SM 44:2;2 (LCB 18:1;2-2H2O,LCB 18:0;3-3H2O)
SM 42:3;2 (SM)

5.80E-05
0.0001
0.00011
0.00019
0.00022
0.00029
0.00033
0.00034

Top 10 most significantly different
SM species in cortex

p-value

HexCer 42:2;3 (LCB 18:2;2-2H20,LCB 18:1;3-3H2O)
SM 34:0;2 (SM)
SM 38:3;2 (SM)
Hex2Cer 26:1;3 (LCB 18:0;2-2H2O)

3.16E-06
8.54E-06
1.50E-05
2.25E-05

HexCer 40:3;3 (LCB 18:2;2-2H20,LCB 18:1;3-3H2O)
SM 38:3;2 (LCB 18:1;2-2H2O,LCB 18:0;3-3H2O)

2.96E-05
3.80E-05

HexCer 40:3;4 (LCB 18:2;2-2H20,LCB 18:1;3-3H2O)
SM 38:4;3 (SM)

5.40E-05
9.17E-05

HexCer 40:2;4 (LCB 18:1;2-H2O,LCB 18:0;3-2H2O)
Cer 34:4;4 (LCB 18:1;2-2H2O,LCB 18:0;3-3H2O)

0.00013
0.00013

Top 10 most significant different SM species
in Mid-Hind brain region
SM 41:4;2 (LCB 18:1;2-2H2O,LCB 18:0;3-3H2O)
SM 41:4;2 (LCB 18:2;2-2H20,LCB 18:1;3-3H2O)
SM 40:4;3 (LCB 18:1;2-2H2O,LCB 18:0;3-3H2O)
SM 40:4;3 (LCB 18:1;2-H2O,LCB 18:0;3-2H2O)
SM 42:4;2 (LCB 18:1;2-2H2O,LCB 18:0;3-3H2O)
SM 40:1;3 (SM)
SM 38:2;2 (SM)
SM 42:4;3 (LCB 18:1;2-H2O,LCB 18:0;3-2H2O)
SM 42:4;3 (LCB 18:1;2-2H2O,LCB 18:0;3-3H2O)
HexCer 40:2;4 (LCB 18:1;2-H2O,LCB 18:0;3-2H2O)

Table 1: Top10 significantly altered TAG (1-3) and SM (4-6) lipid species in the
cerebellum, cortex and Mid-Hind brain region of rmd mice.
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p-value

p-value
5.27E-08
2.01E-06
2.86E-06
4.75E-06
2.08E-05
2.62E-05
2.77E-05
2.80E-05
4.72E-05
6.35E-05

1

Top 10 most significantly different
MDAG species in cerebellum
p-value
MADAG 46:3+NH4 (-FA 24:0 (NH4))
0.00033
MADAG 46:4+NH4 (-FA 20:4 (NH4))
0.0205
MADAG 44:4+NH4 (-FA 12:3 (NH4))
0.02207
MADAG 44:4+NH4 (-FA 20:4 (NH4))
0.02326
DGDG 24:1+NH4 (-FA 12:1 (NH4))
0.03178
MGDG 36:3+NH4 (-MGDG (NH4))
0.04507
MADAG 42:0+NH4 (-FA 17:0 (NH4))
0.04554
MGDG 36:5+NH4 (-FA 16:3 (NH4))
0.04852
MADAG 46:0+NH4 (-FA 13:0 (NH4))
0.05581
MADAG 38:2+NH4 (-FA 16:0 (NH4))
0.06819

4

Top 10 most significantly different
GPL species in cerebellum
p-value
PE 35:2 (FA 17:1)
1.39E-07
PE 40:4 (FA 22:4)
1.40E-07
PE 40:4 (FA 18:0)
3.02E-07
CL 72:3 (FA 18:1)
7.34E-07
CL 78:7 (FA 22:4)
3.24E-06
PE 40:3 (FA 22:3)
6.49E-06
PS 44:8 (FA 22:4)
1.97E-05
PS 42:4 (FA 22:0)
2.16E-05
PE 44:8 (FA 22:4)
3.11E-05
PE 38:4 (FA 16:0)
3.20E-05

2

Top 10 most significantly different
MDAG species in cortex
p-value
MADAG 46:5+NH4 (-FA 17:2 (NH4))
0.02421
MGDG 36:4+NH4 (-FA 19:3 (NH4))
0.03798
MGDG 36:4+NH4 (-FA 16:0 (NH4))
0.04239
MGDG 36:4+NH4 (-MGDG (NH4))
0.04267
MADAG 46:5+NH4 (-FA 18:3 (NH4))
0.04425
MGDG 34:2+NH4 (-FA 17:1 (NH4))
0.05998
MADAG 46:2+NH4 (-FA 20:0 (NH4))
0.07857
MADAG 46:2+NH4 (-FA 19:1 (NH4))
0.07962
MADAG 38:1+NH4 (-FA 18:1 (NH4))
0.0814
MADAG 48:7+NH4 (-FA 19:1 (NH4))
0.08166

5

Top 10 most significantly different
GPl species in cortex
p-value
PS 42:4 (FA 20:3)
6.73E-08
PE 36:2 (PE)
3.08E-06
PC 32:2;1+HCOO (LPC pe)
7.83E-06
PC 37:0+HCOO (FA 19:0)
9.02E-06
PS 42:4 (FA 22:1)
1.36E-05
PS 42:4 (FA 20:4)
2.67E-05
PE 38:4 (FA 16:1)
3.05E-05
PC 32:0+HCOO (FA 14:0)
4.92E-05
CL 88:5 (FA 16:1)
6.80E-05
PS 42:4 (-PS)
6.80E-05

3

Top 10 most significantly different
MDAG species in Mid-Hind brain
p-value
MGDG 36:3+NH4 (-MGDG (NH4))
1.89E-06
MGDG 36:4+NH4 (-MGDG (NH4))
5.88E-06
MGDG 36:6+NH4 (-MGDG (NH4))
0.00161
MGDG 36:6+NH4 (-FA 14:0 (NH4))
0.00214
MGDG 36:10+NH4 (-MGDG (NH4))
0.00236
MGDG 34:2+NH4 (-MGDG (NH4))
0.00244
MGDG 36:8+NH4 (-MGDG (NH4))
0.00284
MGDG 32:2+NH4 (-MGDG (NH4))
0.00386
DGDG 22:7+NH4 (-DGDG (NH4))
0.0039
MGDG 34:4+NH4 (-FA 14:2 (NH4))
0.00687

6

Top 10 most significantly different
GPL species in Mid-Hind brain
p-value
PC 38:6;1+HCOO (LPC pe)
2.44E-07
PS 42:4 (FA 20:4)
1.52E-06
CL 78:5 (FA 21:1)
2.08E-06
PE 36:2 (FA 19:1)
6.10E-06
OAHFA_18:0/ 34:1 (18:0 FA)
9.06E-06
PS 42:5 (-PS)
9.24E-06
PS 43:3 (-PS)
1.70E-05
PE 34:1 (FA 18:0)
1.70E-05
PC 38:6;1+HCOO (LPC pe)
1.91E-05
PS 42:4 (FA 22:0)
3.58E-05

Table 2: Top10 significantly altered DAG, MDAG (1-3) and GPL (4-6) lipid species in the
cerebellum, cortex and Mid-Hind brain region of rmd mice.

Tg-rmd mice as test models for cognitive impairments in rmd mutant mice: As described in
chapter 2, the Tg-rmd mice are engineered to express a functional copy of the Chkb gene under a
muscle specific promoter-Titin. These Tg-rmd mice, as shown in chapter 2, have muscle strength
similar to those of the WT mice. Hence, the Tg-rmd mice can be used to test for cognitive
impairments in the CHKB-deficient mice.
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Tg-rmd mice show significantly different lipid profile when compared to controls: Tissue
from the cortex and Mid + Hind brain region of rmd mice were compared with those of rmd+/control mice in order to test for any changes in the lipid profile. Since lipidomic analysis of rmd
mice showed maximum differences in the cortex and mid-hind brain region, we selected these
two brain regions for a detailed lipid profiling using the MS/MSALL technique. Lipid profiling
with MS/MSALL mass spectra suggests significant differences in the major lipid molecules like
TAGs, PE, cardiolipin (CL), phosphatidic acid (PA), SM and MDAG in both positive and
negative mode. Principal component analysis with Pareto scaling shows a distinct separation of
lipid profiles in the test (Tg-rmd) and control (rmd+/-) mice (Fig 16 A-B and 17 A-B). Table
number 3 shows the 10 most significantly altered lipid molecule species with differences in
molecular chain length, branching and saturation.

A

56

B

FIG 16. Lipid differences in the cerebral cortex across genotypes. Principal component
analysis with Pareto scaling in positive (A) and negative (B) ion mode showing significant
differences across genotype of test (Tg-rmd) and control (rmd+/-) mice in cortex region of
brain.

57

A

58

B

FIG 17. Lipid differences in the Mid and Hind brain region across genotypes. Principal
component analysis with Pareto scaling in positive (A) and negative (B) ion mode showing
significant differences across genotype of test (Tg-rmd) and control (rmd+/-) mice in
Mid+Hind brain region.
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1

Top 10 most significantly different lipid species
identified in positive ion mode in cortex
MADAG 44:5+NH4 (-FA 18:1 (NH4))
TAG 54:5+NH4 (-FA 20:4 (NH4))
MADAG 46:2+NH4 (-FA 20:0 (NH4))
SM 42:4;2 (SM)
TAG 56:7+NH4 (-FA 16:0 (NH4))
TAG 52:2+NH4 (-FA 16:0 (NH4))
HexCer 41:3;2 (LCB 18:2;2-2H20,LCB 18:1;3-3H2O)
MADAG 46:4+NH4 (-FA 19:0 (NH4))
GM1 28:1;2 (LCB 18:1;2-H2O,LCB 18:0;3-2H2O)
TAG 54:4+NH4 (-FA 16:0 (NH4))

p-value
0.00054
0.00075
0.00883
0.00884
0.01264
0.01733
0.01775
0.01845
0.01924
0.02124

2

Top 10 most significantly different lipid species
identified in positive ion mode in Mid-Hind brain
Cer 36:1;2 (LCB 18:0;2-H2O)
GM1 28:1;2 (LCB 18:1;2-H2O,LCB 18:0;3-2H2O)
Cer 36:1;2 (LCB 18:1;2-2H2O,LCB 18:0;3-3H2O)
SM 36:1;2 (SM)
SM 38:0;4 (SM)
TAG 54:4+NH4 (-FA 18:2 (NH4))
Cer 36:1;2 (LCB 18:1;2-H2O,LCB 18:0;3-2H2O)
GM1 48:1;4 (LCB 18:1;2-2H2O,LCB 18:0;3-3H2O)
TAG 52:4+NH4 (-FA 18:2 (NH4))
SM 36:1;4 (SM)

p-value
3.25E-06
3.61E-06
6.47E-06
6.58E-06
1.09E-05
1.51E-05
1.64E-05
1.84E-05
2.37E-05
2.90E-05

3

Top 10 most significantly different lipid species
identified in negative ion mode in cortex
LPIP 25:5 (PI,PS,CL,PIP,PIP2,PIP3)
PS 44:8 (FA 22:2)
CL 78:7 (FA 17:1)
PE 34:1 (FA 20:1)
PE 38:6;1 (PE)
PC 36:5;1+HCOO (LPC pe)
PS 44:8 (FA 22:6)
PE 38:1;2 (PE)
PE 34:1 (FA 18:0)
PA 36:2 (PA,PG,PI,CL,PIP,PIP2)

p-value
0.00058
0.00125
0.00248
0.00285
0.00433
0.00468
0.00506
0.00768
0.00849
0.00861

4

Top 10 most significantly different lipid species
identified by negative ion mode in Mid-Hind brain
LPIP2 20:2 (PA,PG,PI,CL,PIP,PIP2,PIP3)
PE 37:1 (FA 17:0)
PS 42:0 (-PS)
PS 40:2 (FA 18:0)
PE 37:1 (FA 18:0)
CL 84:5 (FA 20:1)
CL 84:4 (FA 20:1)
PE 37:1 (FA 20:0)
PS 34:2 (FA 18:1)
PE 37:1 (FA 19:1)

p-value
5.52E-11
9.34E-11
3.58E-10
4.15E-10
4.47E-10
8.16E-10
1.95E-09
2.65E-08
4.45E-08
5.15E-08

Table 3: Top 10 significantly altered lipid species in the cortex and Mid-Hind brain region
of test (rmd) and control (rmd+/-) mice, demonstrating changes in branch length, side chains
and saturation.

Absence of cognitive defects in Tg-rmd mice: Mass spectrometry MS/MSALL analysis shows
significant differences in the lipid profiles of Tg-rmd when compared to the test (rmd+/-) mice.
To test the possible impact of these changes on cognitive performance, we ran the Tg-rmd mice
on assays including spontaneous alternation, spontaneous alternation with delay and on paired
associates learning to test them for working and short-term memory and learning. When placed
in a maze with multiple arms, mice tend to alternate arm entry and not re-enter an arm. Hence,
this Y-maze set-up can be used to asses working memory dependent primarily on the intact
hippocampus (Sukoff Rizzo et al., 2018). Spontaneous alternation, as a test for working memory,
in Tg-rmd mice showed no significant differences in percent alternation between the arms
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(males, p=0.59 and females, p=0.80) (Fig 18 A-B) and no significant differences in the total arm
entries (males, p=0.21 and females, p=0.90) (Fig 18 C-D).

A

B

Males

ns

100

60

chance
50%

40
20

Control

chance
50%

40

0

Tg-rmd

D

Males

Control

Tg-rmd

Females

D

80

ns
80

ns

60

Total Arm Entries

Total Arm Entries

60

20

C

40
20
0

ns

80

% alternation

% alternation

80

0

Females
100

Control

60
40
20
0

Tg-rmd

Control

Tg-rmd

FIG 18. Testing working memory in Tg-rmd mice. Spontaneous alternation to test working
memory in Tg-rmd mice shows no significant differences between Tg-rmd and control
(rmd+/-) mice. Percent alternation between arms in males (p=0.59) and females (p=0.80) is
not significantly different between Tg-rmd and control mice (A-B). Total arm entries in
males (p=0.21) and females (0.90) are not significantly different between Tg-rmd and
control mice (C-D).
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Short-term recognition memory in mice is assessed using novel spatial recognition using the Ymaze with visual cues at the end of each arm. In this test, mice tend to prefer exploring the
“novel” arm after the 10 min break in the test as opposed to the two arms it was previously
allowed to explore. In the spontaneous alternation with delay test, the percent duration of time
spent in each arm after the 10 min break was not significantly different between the two groups
in males (p>0.99) and females (p=0.98) (Fig 19 A-B). The Tg-rmd males (p=0.88) and females
(p=0.22) did not show significant differences in the total arm entries when compared to the
control mice (Fig 19 C-D).
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19. Testing for short-term memory in Tg-rmd mice. Tg-rmd mice do not show significant
differences when compared to the controls in the percent duration of time spent in each
arm with the males showing p>0.99 and females showing p=0.98 (A-B). The total arm
entries for males (p=0.88) and females (p=0.22) were also not significantly different
between the two groups (C-D).
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Both the Y-maze tests suggest that there is an absence of impairments in working memory and
short-term memory in the Tg-rmd mice.
Paired associates learning test was used to test for learning impairments in Tg-rmd mice.
In this test, the mice are required to learn to associate a given object with a particular location.
The mice were trained until they attained an 85% correct criterion over three consecutive
sessions. Post the pre-training period, the mice are required to complete all trials of the test with
80% accuracy over three consecutive days.
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FIG 21. Testing for learning impairments in Tg-rmd mice. Tg-rmd males did not show any
significant differences from controls in the PI task, p=0.66 and in the dPAL task, p=0.24.
Tg-rmd females show slower response with a significant difference in the PI task, p=0.029
and no significant differences in the dPAL task, p=0.65.

Days to criteria for the punish incorrect (PI) task and the paired associates analysis (dPAL) were
analyzed post the pre-training period, in order to test for cognitive impairments (Bartko,
Vendrell, Saksida, & Bussey, 2011)(Bussey, Dias, Amin, Muir, & Aggleton, 2001). The Punish
incorrect task was used as a pre-dPAL assessment, in which mice were trained to select a square
that was lit. Failure to do so resulted in no reward and a period of ‘light out’. An 85% correct
selection in the punish incorrect task for three consecutive days resulted in progressing to the
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paired associates learning (dPAL) task where the mice tasked to choose a particular object at a
particular location on the screen. A rate of 80% correct choices for three consecutive days
resulting in completion of the task. It was observed that the Tg-rmd males were not significantly
different from the controls in the PI (p=0.66) and dPAL (p=0.24) task (Fig 21 A-C). The Tg-rmd
females on the other hand, completed the PI task in a slightly shorter span of time (p=0.029) (Fig
22 B) but did not perform any different in the dPAL task (p=0.65) (Fig 21 D). This was further
confirmed by the learning curve demonstrated in the first 10 days of the PI and dPAL tasks. The
males showed a difference in rate of learning in both the PI and dPAL task learning curves in the
first 10 days but this did not affect the outcome of the two assays(Fig 20 A-D).
These behavioral tests suggest that the Tg-rmd mice do not show any signs of cognitive
impairments.

Aging does not lead to memory deficits in Tg-rmd mice.
The initial testing for memory deficits were performed with mice aged 8-10 weeks. In order to
test whether Tg-rmd mice show spatial awareness deficits or memory deficits with aging, we
repeated the spontaneous alternation and spontaneous alternation with delay assays on them, post
completion of the dPAL test at around 9 months of age.
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Fig 22. Testing working memory in aged Tg-rmd mice. Aged Tg-rmd males and females did
not show any significant differences from controls in total arm entries (p=0.51 and p=0.12,
respectively) and in the percent alternation between arms (p=0.72 and p=0.69,
respectively).

Spontaneous alternation test results showed no significant differences in total arm entries
between Tg-rmd males or females and their respective controls with males showing a p=0.51 and
females that of 0.12, respectively (Fig 22 A). In percent alternation males showed a P value of
0.72 and females that of 0.69 respectively, suggesting no significant differences from control
group (Fig 22 B).
For spontaneous alternation with delay, the delay time for re-introduction into the Ymaze was reduced from 10 min to 5 min, to take into consideration delay dependent effects in
aged mice.
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FIG 23. Testing short-term memory in aged Tg-rmd mice. Aged Tg-rmd males and females
did not show any significant differences in the percent duration spent in the arms (males,
p=0.64 and females, p=0.62) (A-B) and in the total arm entries (males, p=0.47 and females,
p=0.28) (C-D).

Spontaneous alternation performed on aged Tg-rmd and control mice showed no significant
differences in the percent duration spent in each arm of the Y-maze (p=0.64) (Fig 23 A) and in
the total arm entries (p=0.62) (Fig 23 C). The Tg-rmd females too showed no significant
differences when compared to the aged matched controls in the percent duration spent in each
arm of the Y-maze (p=0.47) (Fig 23 B) and in the total arm entries (p=0.28) (Fig 23 D). In the
spontaneous alternation with delay, the control females do not show preference for the novel
arm, thus failing the assay and hence cannot be used to draw conclusions with certainty.
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The males used in these assays suggest that even in >6 months aged Tg-rmd mice, there
are no working or short-term memory deficits observed from these tests conducted. Together, the
results indicate that from these particular behavioral tests, no spatial awareness, memory deficits
or cognitive impairment could be modelled in the Tg-rmd mice.

Expression of Chkb transgene does not influence spatial awareness and memory in mice.
Addition of a transgene may result in impairments in cognition and memory which are apparent
in the spontaneous alternation and delayed spontaneous alternations tests
(https://med.stanford.edu). In order to test this, the Tg-WT mice were tested for spatial
awareness on the Y-maize through the spontaneous alternation and spontaneous alternation with
delay tests.
For this test, Tg-Wt and WT mice (N=10 mice/sex/genotype) were acclimatized and tested for
spontaneous alternation on the y-maze as previously described. The Tg-WT mice did not
perform any differently than the WT controls with the total number of arm entries and percent
spontaneous alternation between the two groups being similar (Fig 24 A-D).
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Fig 24. Testing of spatial awareness in Tg-WT mice. The Tg-WT mice when tested on the ymaze for spontaneous alternation were not significantly different from the control WT
mice in the total number of arm entries with p vales of 0.43 and 0.56 in males (A) and
females (B) respectively. The Tg-WT mice were not significantly different from the controls
in the percent spontaneous alternation with p values of 0.25 and 0.63 in males (C) and
females (D) respectively. N=10 mice/sex/genotype aged 8-10 weeks. Error bars represent
SD.
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Young rmd mice do not show impairments in spatial awareness and memory
When tested for short-term memory on the y-maze using the spontaneous alternation with
delay assay, the male and female controls did not show preference for the novel arm and hence
did not pass the test. In this test, too an N of 10 mice/sex/genotype aged 8-10 weeks were used
and were acclimatized as per the testing protocol previously described (Fig 25 A-D).
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The spontaneous alternation assay and the percent spontaneous alternation in the spontaneous
alternation with delay test suggest the transgene has no detrimental effect on the spatial
awareness and short-term memory of the mice.
Since Tg-rmd and Tg-WT mice do not show any differences in their spatial awareness
and memory when compared to control mice, we decided to test rmd mutant mice directly for
differences in these abilities. However, since the rmd mice become physically impaired due to
their hindlimb dragging at 8 weeks of age, we tested for the presence of these impairments at 4-5
weeks of age.
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FIG 26. Testing working memory in young rmd mice. rmd mutant mice are not significantly
different from their WT controls in total arm entries (males, p=0.07) and (females, p=0.09)
(A-B) and in the percent of spontaneous alternation (males, p=0.33 and females, p=0.96)
(C-D).
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Spontaneous alternation showed rmd are not significantly different from their age-matched
controls (WT mice). The males and females showed a P value of 0.07and 0.09 respectively in the
total number of arm entries (Fig 26 A-B). The percent alternation between arms of the Y-maze
were also not significantly different in the rmd males and females with a P value of 0.33 and 0.96
respectively (Fig 26 C-D).
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FIG 27. Testing short-term memory in young rmd mice. rmd mice when tested for
spontaneous alternation with delay did not show preference for the novel arm greater than
chance percent in both males and females with no significant differences between the rmd
and control groups (males, p=0.62 and females, p=0.61) (A-B). rmd mutant mice did not
show significant differences in the total number of arm entries when compared to controls
(males, p=0.43 and females, p=0.59) (C-D).
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The rmd mutant mice were tested for deficits in memory using the spontaneous alternation with
delay test on the Y-maze. The rmd mice did show a preference to spend greater time in the novel
arm. The control mice, on the other hand, showed a greater preference for the familiar arm. Both
the rmd and the control mice did not any significant differences to each other (males, p=0.62 and
females, p=0.61) (Fig 27 A-B). The rmd mice did not show any significant differences in the
total arm entries when compared to their aged-matched controls (males, p=0.43 and females,
p=0.59) (Fig 27 C-D).
This suggests that the rmd mice do not model cognitive impairments at a very young age
(immediately post-wean).

Discussion:
Changes in brain lipid composition has been indicated in cognitive impairments, anxiety and
depression (Müller et al., 2015)(Vitali, Wellington, & Calabresi, 2014). Previous literature shows
that there lies a direct correlation between the lipid composition of brain tissue and cognitive
impairments, with persons suffered from brain trauma and diseases like Alzheimer’s, mild
cognitive impairments and dementia showing a greater percent of short chain, unsaturated fatty
acids in their brain tissue when compared to brain tissue from unaffected population (R. B. Chan
et al., 2012)(Wood, 2012)(Cunnane et al., 2012). It has been shown that choline and hence PC
are important molecules in normal brain development(G. B. ANSELL, 1971)(Zeisel SH,
1992)(Zweigner et al., 2004)(Sanders & Zeisel, 2007). Not much is known about the lipid
profiles in the brain of C57BL/6J mice or in that of AD mouse models and additional insights in
this filed are necessitated by the recent progress in Alzheimer’s and mild cognitive impairment
research.
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We have shown that significant lipid profile differences exist in brain tissue from rmd
and Tg-rmd mice when compared to unaffected mice, justifying the use of these mice in order to
model the cognitive impairments seen in MDCMC patients in these mouse models. We have
shown that since the rmd mice lack muscle strength required for performing certain basic
behavioral tasks, the Tg-rmd mice were used as test subjects for behavioral tests including
spontaneous alternation, spontaneous alternation with delay and dPAL, all of which require
considerable physical activity. Besides this, tests like the dPAL can continue for more than 6
months by the time of which the rmd mice would be unable to perform at the same level as at 4-5
weeks of age, further justifying the use of Tg-rmd mice as test subjects. Behavioral testing for
spatial awareness, memory and associated learning in the Tg-rmd mice did not show any
significant differences from their controls. Tests for spatial awareness and short-term memory
failed to show significant differences between >6 months aged Tg-rmd and aged-matched
controls. A repeat of the spatial awareness and short-term memory tests on young rmd mice did
not show cognitive impairments at 4-5 weeks of age. Together, it has been shown that across
different genotypes and at different ages, the differences in brain lipid profiles could not be
translated behaviorally using the specified methods of analysis and testing. The Cortex and in
particular the hippocampus plays an important part in memory, speech and spatial awareness.
The hippocampus and the lipids within has been shown to be affected with increasing age and in
conditions like AD (Delion et al., 1997). The y-maze assay, mainly tests the hippocampal region
of the brain and has been used to correlate changes in hippocampus with memory, spatial
awareness and aging (Ira et al., 1999).
Our research has helped bridge the gap in knowledge pertaining to lipid profiles of brain
in B6 mouse models. Additionally, we have also profiled the rmd mouse model that lacks Chkb
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gene necessary for production of PC, an important lipid molecule required for normal brain
function and development. Our data used the MS/MSALL technique to meticulously identify all
the different lipid molecules at different chain lengths and saturation levels, contributing to the
building repository of information pertaining to lipid profiles in mouse models of cognitive
impairments. This can help correlate information from aging, drug use and diet and obesity
studies in order to gain more perspective on treatment methods and effects on human population.
Cognitive impairments demonstrated by MDCMC patients fall in a broad spectrum
ranging from low IQ, speech deficits, memory loss, inability to learn and lack of social cues
resulting in failure to interact and integrate in a social environment (Gutiérrez Ríos et al.,
2012)(Castro-Gago et al., 2014)(Oliveira et al., 2015)(Cabrera-Serrano et al., 2015)(S. Sparks &
Harper, 2001). The assays I used tested only a few aspects within this spectrum. We have shown
that the rmd and Tg-rmd mice do not demonstrate deficits in spatial awareness or memory and
learning, however, this covers only a part of the cognitive spectrum observed in MDCMC
patients and hence does not imply a lack of speech and social interaction difficulties.
It has been shown that background strains of mice influence their performance in
cognitive tasks thus impacting their phenotype. C57BL/6J mice perform better in the Morris
water maze task but have a greater predominance of approach towards a DBA/2J females
whereas DBA mice perform worse than C57BL/6J on the Morris water maize but have a greater
predominance of avoidance towards a DBA/2J female. Different strains like Friend Virus B NIH
Jackson (FVB), DBX, 129, DBA SJL, each has a different effect over cognitive functions of the
mouse (Hall & Roberson, 2012)(Brodkin, Hagemann, Nemetski, & Silver, 2004)(Lassalle,
Halley, Daumas, Verret, & Francés, 2008). Our rmd and Tg-rmd mice have been bred on a
C57BL/6J background and it may be possible that changing this background could result in
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changes in the outcome of the behavioral assays performed above. These background strains also
influence the effects of aging on the mice, thus indirectly influencing cognitive functions.
In summary we conclude that there are significant differences in lipid profiles in the brain
of rmd and Tg-rmd mice compared to WT and rmd+/- mice and that these differences do not
translate to observable differences in the behavioral assays for learning and memory. This study
is impactful since it is one of the first that compares dynamic and detailed lipid profiles amongst
different ages and phenotypes of mice in a CHKB deficient environment, providing the first of
its kind study for further characterization of MDCMC patients.

Materials and Methods:
Lipidomic analysis: Brain and liver from Tg-rmd, rmd, WT and rmd+/- were harvested (N=4
mice/sex/genotype). The brain was separated into cortex, cerebellum and mid+hind brain region.
The samples were homogenized and process as described by Liaw et al. Unbiased MS/MSALL
lipidomic shotgun analysis was performed on these samples using the method described by Liaw
et al.(Liaw et al., 2016).

Behavioral Assays for cognition: Spontaneous alternation, Novel spatial recognition and Paired
Associates Learning (dPAL) were used to assess working memory, short-term memory and
learning.
Spontaneous alternation: Spontaneous alternation tests the working memory of mice and
depends on their intact hippocampus. For this test 5-10 mice/sex/genotype were used. The mice
were placed in a three-armed Y-shaped maze with no visual cues inside the maze and a perimeter
curtain to minimize extra maze cues (Sukoff Rizzo et al., 2018). An 8 min trial was run on each
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mouse under a 50 lux environmental lighting conditions. Behavioral tracking software was used
to track the movement of the mouse based on its center point, thus recording its entry into each
arm. Total arm entries and time spent in each arm are calculated.
Novel spatial recognition/ Spontaneous alternation with delay: This test assesses short-term
memory in mice. 10 mice/sex/genotype were used for this assay. The mice were tested in a threearmed Y-shaped maze with dimensions as specified by Rizzo et al. (Sukoff Rizzo et al., 2018).
The three arms are designated as start arm, familiar arm and novel arm. The novel arm is closed
off using a black polycarbonate wall and the mice are allowed to explore in the start and familiar
arm for 10 minutes. After this the mice are removed and allowed a delay time of 10 minutes post
which they are re-introduced in the maze with access to the novel arm, thus giving access to all
three arms of the maze, and are allowed to explore for 5 minutes. Behavioral tracking software is
used to track the movements of the mice with their center point as reference point and is used to
calculate total arm entries, total time spent in each arm in the first 10 minutes and during the 5
minutes of re-introduction in the maze. For calculations of learning curve, first 10 days were
calculated as during this period only one mouse finished the test, the data from this mouse was
impugned form day 7 to day 10 in order to maintain consistency.
Paired associates learning (dPAL): The dPAL assay was used to assess learning in mice (N= 8
mice/sex/genotype). The mice were food restricted and their body weights reduced prior to the
test and then maintained at about 80%-85% free feeding throughout the testing period (Bussey et
al., 2001). The testing chamber consists of a black opaque plastic triangular space with the
touchscreen placed at the base of the triangle. An opaque plastic screen with three windows is
placed ahead of the touchscreen, facilitating three options that the animal can nose-poke and
choose from. A pellet chamber is present at the apex of the triangle. This chamber is attached to
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a vacuum pump that dispenses about 20µl of strawberry milk into the chamber as a reward. For
selection, three novel stimuli (picture) were presented to the animal, one per window. The animal
has to select the correct stimuli at the correct location (window) in order to receive the reward
(Brigman et al., 2008). Correct choice would lead to a cue and dispensing of strawberry milk in
the pellet chamber while an incorrect choice would lead. The mice were trained until they
attained an 80% correct criterion over three consecutive sessions. Post the pre-training period,
the mice are required to complete all trials of the test with 80% accuracy over three consecutive
days. The tracking software is used to measure time taken to complete each trial, percent correct
and many other values. For calculations of learning curve, first 10 days were calculated as during
this period only one mouse finished the test, the data from this mouse was impugned form day 7
to day 10 in order to maintain consistency.

Statistical analysis: All the experiments were performed at the Jackson Laboratory, Bar Harbor.
All mouse handling, testing, and analysis were performed blinded for mouse genotype. Where
appropriate, statistical significance was calculated using Student’s t-test or 2-way ANOVA with
post-hoc Bonferroni corrections unless otherwise noted. Calculations were performed using
Prism 7.0c software for Mac OS X and any significant differences (p<0.05) between test and
control strains are denoted by an asterisk symbol. For behavioral assays, each mouse is treated as
a biological control and each test has a different number of statistical control experiments run on
one mouse.

Protocols for open field, rotarod, spontaneous alternation, spontaneous alternation with
delay were conducted as described in chapter 2.
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CHAPTER 4
GENETIC AND THERAPEUTIC MECHANISMS TARGETED TOWARDS THE
RESCUE OF RMD MUTANT PHENOTYPE

1. Mitofusin as a modifier gene for the rescue of rmd muscular dystrophy
In WT mice, many muscle cells or myofibers come together forming a bundle that forms an
entire muscle. Each muscle fiber is bound by a plasma membrane called sarcolemma. The
sarcolemma forms invaginations called Transverse tubules (T-tubules) that penetrate the muscle
fiber and tightly associate with the sarcoplasmic reticulim (SR), forming the junctional SR (AlQusairi & Laporte, 2011). A T-tubule associated with a terminal cisternae on each side forms a
structure called the triad (Fig 28 A-B). In a muscle fiber, the excitation-contraction (EC)
coupling is mediated by Ca2+ ions that are stored and provided by the SR. These Ca2+ form the
secondary messengers and play an important role in the contraction of muscle fibers. Due to its
structure and close contact with the SR, the muscle triad plays a principle role in EC coupling
and hence in muscle contraction (Al-Qusairi & Laporte, 2011). In a rmd mouse, the triad
structure is destroyed due to the sheer size of the mitochondria (Fig 29). All the other proteins
involved in EC coupling are shifted thus negatively impacting Ca2+ ion storage and exchange and
thus abilities of the muscle to contract (Fig 30 A-B).
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B

Muscle
triad
structure

FIG 28. TEM images of muscle triad structure. (A) Shows the muscle triad structure
which plays a principle role in EC coupling and hence in muscle contraction. (B)
Represents a birds eye view of a general muscle structure with intact muscle triads at
10000X.

FIG 29. Representational image of WT and rmd muscle structure. A representation of the
difference in muscle structure of an unaffected and rmd mouse.

80

A

B

FIG 30. TEM images of gastrocnemius muscle from WT and rmd mice. (A) Represents
skeletal muscle from an unaffected WT mouse, showing normal mitochondrial phenotype
and distribution (B) Represents skeletal muscle from a rmd mutant mouse, showing
megamitochondria and disrupted muscle architecture as a result of the megamitochondria.
N= 4 mice/sex/genotype aged 4-6 weeks.

As seen in chapter 2, rmd mutant mice show an increase in mitochondrial area but a
decrease in mitochondrial numbers. We hypothesize that this phenomenon directly correlates to a
defect in mitochondrial fission or fusion, the correction of which, may enable normal sized
mitochondria, which will in turn normalize the disrupted muscle architecture and will thus enable
regular Ca2+ ion exchange and muscle contraction, thus rescuing the rmd phenotype.
In mammals, both mitochondrial fission and fusion are important events in maintaining
mitochondrial morphology, mitochondrial DNA (mtDNA) stability, respiratory capacity,
response to cellular stress and apoptosis. In mammals, there are three important fusion proteinsmitofusin 1 (Mfn1), mitofusin 2 (Mfn2) and optic atrophy 1 (OPA1) that facilitate proper
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mitochondrial fusion. Mfn 1 and 2 are transmembrane GTPases embedded in the mitochondrial
outer membrane , whereas OPA1 is a dynamin related GTPase associated with the mitochondrial
inner membrane or intermembrane space (D. C. Chan, 2012).
Depletion of any one of the three fusion proteins results in a decrease in mitochondrial
fusion (D. C. Chan, 2012). Previous literature shows that Mfn 1 and 2 can exist as both
homotypic and heterotypic oligomers and can cooperate as well as act individually to promote
mitochondrial fusion (H. Chen et al., 2003). Mice heterozygous for Mfn1 or Mfn2 null mutations
demonstrate full viability and fertility but homozygous mutants for either gene are embryonically
lethal. Preliminary studies by Chen, et al. indicate that double homozygous embryos show
greater developmental delay and die earlier than either single mutant. Hybrid cell fusion assays
(PEG fusion assays) determined that Mfn1 or Mfn2 deficient cells have severely fragmented
mitochondria with deficient mobility. This fragmentation is caused by a reduction in fusion
caused by loss of Mfn1 or Mfn2. Additionally, it was noted that in 10% of fused Mfn1 mutant
cells, the mitochondria did not spread readily throughout the cytoplasm but instead remained in
distinct sectors of red and green fluorescence showing a ‘sectoring effect’ (H. Chen et al., 2003).
Hence, in order to test our hypothesis, that reducing the size of megamitochondria in our
rmd mice would have a positive effect on muscle morphology and function, we engineered a
muscle-specific Mfn1 null mouse and a separate muscle-specific Mfn2 mouse that we bred
separately to our rmd strain resulting in a Mfn1-/-HSA.Cre.Tg+/-rmd/rmd and a Mfn2-/HSA.Cre.Tg+/-rmd/rmd strain respectively. The HSA.Cre transgenic mouse has a Human AlphaSkeletal Actin promoter driven Cre recombinase. This when bred to a loxp flanked sequence of
interest, will result in a Cre mediated deletion of the sequence of interest in the skeletal muscle
only. We hypothesized that the megamitochondria of rmd mice when coupled with the
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fragmented mitochondria of the Mfn1/2-/-HSA.CreTg+/- mouse will result in normal (WT) sized
mitochondria which would restore muscle architecture and hence the dystrophic phenotype in the
rmd mutant mice. This strategy would serve as a proof of concept for the possible strategy for the
knockdown of Mfn1 and 2 genes in MDCMC patients for a restoration of their muscle fiber
structure and hence disease phenotype.

Results:
Partial rescue of mitochondrial dimensions in Mfn1-/-HSA.CreTg+/-rmd/rmd and Mfn2-/HSA.CreTg+/-rmd/rmd mice: Mfn1/2-/-HSA.Cre.Tg+/-rmd/rmd mice were generated using the
breeding scheme represented in Fig 30.

FIG 31. Breeding scheme to obtain Mfn1/2-/-HSA.Cre.Tg+/-rmd/rmd mice.
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Mfn1/2-/-HSA.Cre.Tg+/-rmd/rmd mitofusin mice were analyzed for mitochondrial areas to
test for histological changes in cellular phenotype. Gastrocnemius skeletal muscles were
harvested and stained for TEM analysis (4 mice/sex/genotype aged 4-6 weeks). It can be seen
that the mitochondria in Mfn1/2-/-HSA.Cre.Tg+/-rmd/rmd mice have area in between that of
Mfn1/2-/-HSA.Cre.Tg+/-rmd+/+ and rmd mice (Fig 32 A-C) and (Fig 33 A-C). Quantitative
analysis shows that the mitochondrial areas of Mfn1/2-/-HSA.Cre.Tg+/-rmd/rmd are significantly
greater (p<0.0001) than those from Mfn1/2-/-HSA.Cre.Tg+/-rmd+/+ mice and significantly smaller
than those from rmd mutant mice (p<0.0001) (Fig 34 A-B).

FIG 32. Mitochondrial dimensions across Mfn1 genotypes. (A) represents skeletal muscle
from Mfn1-/-HSA.Cre.Tg+/- mouse with highly fragmented mitochondria and (B)
represents skeletal muscle from Mfn1-/-HSA.Cre.Tg+/- rmd+/+ mice with mitochondria in
between that of Mfn1-/-HSA.Cre.Tg+/- and rmd mice. (C) represents skeletal muscle from a
rmd mouse showing megamitochondria. N=4 mice/sex/genotype aged 4-6 weeks.
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FIG 33. Mitochondrial dimensions across Mfn2 genotype. (A) represents skeletal muscle
from Mfn2-/-HSA.Cre.Tg+/- mouse with highly fragmented mitochondria and (B)
represents skeletal muscle from Mfn2-/-HSA.Cre.Tg+/- rmd+/+ mice with mitochondria in
between that of Mfn2-/-HSA.Cre.Tg+/- and rmd mice. (C) represents skeletal muscle from a
rmd mouse showing megamitochondria. N=4 mice/sex/genotype aged 4-6 weeks.
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FIG 34. Mitochondrial areas across Mfn1 and Mfn2 genotypes. (A-B) show a statistical
analysis for mitochondrial areas in the different genotypes of analyzed mice. In summary,
Mfn1/2-/-HSA.Cre.Tg+/- rmd+/+ mice show mitochondrial area significantly larger than
those of Mfn1/2-/-HSA.Cre.Tg+/- mice but smaller than those of rmd mice, indicating a
partial rescue in mitochondrial dimensions. N=4 mice/sex/genotype aged 4-6 weeks. Error
bars represent mean with SD.

Mitochondrial area analysis (performed as described in chapter 2) indicated a partial rescue in
the areas of Mfn1/2-/-HSA.Cre.Tg+/-rmd/rmd mice compared to the rmd and Mfn1/2-/HSA.Cre.Tg+/-rmd+/+ mice.
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Changes in mitochondrial dimensions do not rescue body weights and grip strength: Mfn1-/HSA.CreTg+/-rmd/rmd and Mfn2-/-HSA.Cre.Tg+/-rmd/rmd mice were weaned at 3 weeks of age
and then weighed and tested for wire hang abilities for a period of 7 weeks post wean. Body
weight curves show that Mfn1-/-HSA.Cre.Tg+/-rmd/rmd or Mfn2-/-HSA.Cre.Tg+/-rmd/rmd mice
were not significantly different from the rmd mice (Fig 35, 36) and showed no gross
improvements in overt phenotype (Table 4, 5). Testing for grip strength on the wire hang
apparatus showed no significant differences in the hang time between Mfn1-/-HSA.Cre.Tg+/rmd/rmd or Mfn2-/-HSA.Cre.Tg+/-rmd/rmd and rmd mice indicating that a muscle specific
deletion of Mfn 1 or Mfn2 gene in a rmd mouse did nor rescue muscle strength phenotype (Fig
37, 38) (Table 6,7). A muscle specific deletion of mitofusin did not rescue the forelimb
deformity seen in the rmd mice, affecting their ability to perform on the hanging wire assay.

FIG 35. Growth curve across Mfn1 genotypes. Mfn1-/-HSA.Cre.Tg+/-rmd/rmd weights curve
There are no significant differences in the weights of Mfn1-/-HSA.Cre.Tg+/-rmd/rmd and
rmd mutant mice. N= 4 mice/sex/genotype.
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Tukey's multiple comparisons test

Mean Diff.

Mfn1-/-HSA.Cre.Tg+/-rmd+/+ vs. Mfn1-/-HSA.Cre.Tg+/rmd+/Mfn1-/-HSA.Cre.Tg+/-rmd+/+ vs. Mfn1-/-HSA.Cre.Tg+/rmd/rmd

3.103
11.55

Mfn1-/-HSA.Cre.Tg+/-rmd+/+ vs. rmd

9.984

Mfn1-/-HSA.Cre.Tg+/-rmd+/+ vs. rmd +/Mfn1-/-HSA.Cre.Tg+/-rmd+/- vs. Mfn1-/-HSA.Cre.Tg+/rmd/rmd
Mfn1-/-HSA.Cre.Tg+/-rmd+/- vs. rmd

3.296
8.447
6.881

Mfn1-/-HSA.Cre.Tg+/-rmd+/- vs. rmd +/-

0.1933

Mfn1-/-HSA.Cre.Tg+/-rmd/rmd vs. rmd

-1.565

Mfn1-/-HSA.Cre.Tg+/-rmd/rmd vs. rmd +/-

-8.253

rmd vs. rmd +/-

-6.688

95.00% CI of
diff.

Significant?

0.5921 to
5.614
9.039 to
14.06
7.748 to
12.22
0.7854 to
5.807
5.896 to 11
4.6 to 9.163
-2.358 to
2.744
-3.847 to
0.7164
-10.8 to 5.702
-8.97 to 4.406

Summary

Adjusted P
Value

Yes

**

0.0081

Yes

****

<0.0001

Yes

****

<0.0001

Yes

**

0.0042

Yes
Yes

****
****

<0.0001
<0.0001

No

ns

0.9995

No

ns

0.3136

Yes

****

<0.0001

Yes

****

<0.0001

Table 4: Tukey’s multiple comparisons test for weights on different Mfn1 genotypes.
This table shows that there are no significant differences in the weights of Mfn1-/HSA.Cre.Tg+/-rmd/rmd and rmd mice showing no improvements in the wire hang / grip
strength by a muscle specific deletion of Mfn1 gene in rmd mice.

FIG 36. Growth curves across Mfn2 genotypes. Mfn2-/-HSA.Cre.Tg+/-rmd/rmd weights curve
There are no significant differences in the weights of Mfn2-/-HSA.Cre.Tg+/-rmd/rmd and
mutant rmd mice. N= 4 mice/sex/genotype.
88

Tukey's multiple comparisons test

Mean
Diff.

95.00% CI of
diff.

Mfn2-/-HSA.Cre.Tg+/-rmd+/+ vs. Mfn2-/-HSA.Cre.Tg+/-rmd+/-

-2.41

-5.385 to
0.5654

No

ns

0.1671

Mfn2-/-HSA.Cre.Tg+/-rmd+/+

vs.

Mfn2-/-HSA.Cre.Tg+/-rmd/rmd

Significant? Summary

Adjusted P
Value

7.95 4.975 to 10.93

Yes

****

<0.0001

Yes

****

<0.0001

Mfn2-/-HSA.Cre.Tg+/-rmd+/+ vs. rmd+/-

6.058 3.445 to 8.671
-3.605 to
2.345
-0.63

No

ns

0.9755

Mfn2-/-HSA.Cre.Tg+/-rmd+/-

10.36 7.179 to 13.54

Yes

****

<0.0001

8.468 5.623 to 11.31
-1.401 to
4.961
1.78
-4.737 to
0.953
-1.892
-11.76 to 5.399
-8.58
-9.533 to 3.843
-6.688

Yes

****

<0.0001

No

ns

0.5216

No

ns

0.3459

Yes

****

<0.0001

Yes

****

<0.0001

Mfn2-/-HSA.Cre.Tg+/-rmd+/+ vs. rmd

vs.

Mfn2-/-HSA.Cre.Tg+/-rmd/rmd

Mfn2-/-HSA.Cre.Tg+/-rmd+/- vs. rmd
Mfn2-/-HSA.Cre.Tg+/-rmd+/- vs. rmd+/Mfn2-/-HSA.Cre.Tg+/-rmd/rmd vs. rmd
Mfn2-/-HSA.Cre.Tg+/-rmd/rmd vs. rmd+/rmd vs. rmd+/-

Table 5: Tukey’s multiple comparisons test for weights on different Mfn2 genotypes.
This table shows that there are no significant differences in the weights of Mfn2-/HSA.CreTg+/-rmd/rmd and rmd mice showing no improvements in the wire hang / grip
strength by a muscle specific deletion of Mfn2 gene in mutant rmd mice.
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FIG 37. Wire hang assay on Mfn1-/-HSA.Cre.Tg+/-rmd/rmd mice. Wire hang assay in Mfn1-/HSA.Cre.Tg+/-rmd/rmd mice. Wire hangs show no significant differences in hang time of
Mfn1-/-HSA.Cre.Tg+/-rmd/rmd and rmd mice. Mfn1-/-HSA.Cre.Tg+/-rmd+/- mice show
hanging times in between those of WT (B6) mice and Mfn1-/-HSA.Cre.Tg+/-rmd/rmd mice
indicating probable partial effect of muscle specific deletion of Mfn1 gene in WT mice. N=
4 mice/sex/genotype.

Tukey's multiple comparisons test

Mean Diff.

Mfn1-/-HSA.Cre.Tg+/-rmd+/+ vs. Mfn1-/HSA.Cre.Tg+/-rmd/rmd

34.19

Mfn1-/-HSA.Cre.Tg+/-rmd+/+ vs. rmd

34.19

Mfn1-/-HSA.Cre.Tg+/-rmd+/+ vs. B6
Mfn1-/-HSA.Cre.Tg+/-rmd/rmd vs. rmd

-25.81
0

Mfn1-/-HSA.Cre.Tg+/-rmd/rmd vs. B6

-60

rmd vs. B6

-60

95.00% CI of
diff.

Significant? Summary

22.24 to
46.14
23.04 to
45.34
-37.76 to 13.86
-11.36 to
11.36
-72.14 to 47.86
-71.36 to 48.64

Adjusted P
Value

Yes

****

<0.0001

Yes

****

<0.0001

Yes

****

<0.0001

No

ns

>0.9999

Yes

****

<0.0001

Yes

****

<0.0001

Table 6: Tukey’s multiple comparisons test for Mfn1-/-HSA.Cre.Tg+/-rmd/rmd mice on wire
hang assay.
The table summarizes the statistical significance between the different genotypes for Mfn1
gene tested. There are no significant differences between the wire hang time of Mfn1-/HSA.Cre.Tg+/-rmd/rmd and rmd mice, indicating the muscle specific deletion of Mfn1 gene
in rmd mutant mice does not recue muscle strength phenotype.
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FIG 38. Wire hang assay on Mfn2-/-HSA.Cre.Tg+/-rmd/rmd mice. Wire hang assay in Mfn2-/HSA.Cre.Tg+/-rmd/rmd mice. Wire hangs show no significant differences in hang time of
Mfn2-/-HSA.Cre.Tg+/-rmd/rmd and rmd mice. Mfn2-/-HSA.Cre.Tg+/-rmd+/- mice show
hanging times in between those of WT (B6) mice and Mfn2-/-HSA.Cre.Tg+/-rmd/rmd mice
indicating probable partial effect of muscle specific deletion of Mfn2 gene in WT mice. N=
4 mice/sex/genotype.

Tukey's multiple comparisons test
Mfn2-/-HSA.Cre.Tg+/-rmd+/+ vs. Mfn2-/HSA.Cre.Tg+/-rmd/rmd
Mfn2-/-HSA.Cre.Tg+/-rmd+/+ vs. B6

Mean Diff.

30.2
-29.8

Mfn2-/-HSA.Cre.Tg+/-rmd+/+ vs. rmd

30.2

Mfn2-/-HSA.Cre.Tg+/-rmd/rmd vs. B6

-60

Mfn2-/-HSA.Cre.Tg+/-rmd/rmd vs. rmd
B6 vs. rmd

0
60

95.00% CI of
diff.
20.63 to
39.77
-39.37 to 20.23
20.63 to
39.77
-69.57 to 50.43
-9.567 to
9.567
50.43 to
69.57

Significant? Summary

Adjusted P
Value

Yes

****

<0.0001

Yes

****

<0.0001

Yes

****

<0.0001

Yes

****

<0.0001

No

ns

>0.9999

Yes

****

<0.0001

Table 7: Tukey’s multiple comparisons test for Mfn2-/-HSA.Cre.Tg+/-rmd/rmd mice on wire
hang assay.
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The table summarizes the statistical significance between the different genotypes for Mfn2
gene tested. There are no significant differences between the wire hang time of Mfn2-/HSA.Cre.Tg+/-rmd/rmd and mutant rmd mice, indicating the muscle specific deletion of
Mfn2 gene in mutant rmd mice does not recue muscle strength phenotype.

2. S107 compound for the treatment of muscular dystrophy
Ryanodine receptor 1 (RyR1) is the calcium release channel in the sarcoplasm of the skeletal
muscle required for muscle contraction. Calstabin1 is a sub-unit that stabilized this RyR1 and has
been shown to decrease with age, making RyR1 unstable and hence leaky. It has been shown that
S107 preserves RyR1-calstabin1 binding, stabilizing RyR1, reducing Ca2+ sparks and hence
restoring muscle specific force for improved exercise capacity in aged WT mice (Andersson et
al., 2011)(Mei et al., 2013). Similar RyR1-calstabin1 binding instability has been observed in the
mdx mouse model for Duchenne muscular dystrophy and is predicted to be a major reason for
decreased muscle function in this disease. When mdx mice were supplied 25mg/100ml of S107
compound through drinking water for 7-9 days they showed increased running speed and
duration on the running wheel (Andersson et al., 2012). In a separate study, mdx mice
administered S107 were found to have increased muscle function, voluntary activity and
improved muscle histopathology (Blat & Blat, 2015).
Previous literature provides strong evidence of the involvement in RyR1-calstabin1
binding integrity in prevention of muscular dystrophy and provides evidence for the effect of
S107 in preserving RyR1 and calstabin1 binding. Hence, we decided to test the effects of
supplementation of S107 to our rmd mice via diet. The experimental set-up was similar to that of
the CDP-choline and 50mg/Kg/day of S107 was administered to rmd mice via Clear H2O diet
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gel. Diet gel spiked with the same amount of S107 was also fed to WT mice to test for toxic
effects of S107 in healthy conditions.

Results:
S107 administration did not improve body weight and growth curve of rmd mutant mice
3 weak mice were administered 50 mg/Kg/day of S107 compound by mixing 8.75 mg of S107
compound in 56gms of Clear H2O diet gel and available to the mice for ab libitum consumption.
Clear H2O diet gel was prepared fresh and administered daily. Mice were weighed every week
from the start of the study at 3 weeks and up to 5 weeks of age. No significant improvements in
growth rate were observed in the rmd (MUT) S107 treated mice when compared with historic
data from rmd mice on plain Clear H2O diet gel (p=0.10, 0.26 and 0.56 at 3, 4 and 5 weeks
respectively). rmd S107 administered mice showed a significantly decreased (p<0.0001) growth
curve when compared WT mice administered S107 compound. No significant differences were
observed between the S107 administered WT mice and WT mice on Clear H2O diet gel (historic
data) indicating no toxic effects of supplementation of S107 in healthy conditions (Fig 39).
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FIG 39. Growth curve or rmd mice on S107 supplement: Growth curve of rmd mice on S107
supplementation. No significant improvements in growth curve was observed in the
Mfn1/2-/-HAS.Cre.Tg+/-rmd/rmd S107 treated mice when compared with historic data from
rmd mice on plain Clear H2O diet gel (p=0.10, 0.26 and 0.56 at 3, 4 and 5 weeks
respectively). Mfn1/2-/-HAS.Cre.Tg+/-rmd/rmd S107 administered mice showed a
significantly decreased (p<0.0001) growth curve when compared with Mfn1/2-/HAS.Cre.Tg+/-rmd+/+ (WT) mice administered S107 compound. The Mfn1/2-/HAS.Cre.Tg+/-rmd+/+ mice were not significantly different from the WT mice on plain diet
gel, as seen from historic data. Where; MUT=mutant, WT=wild type. N= 4
mice/sex/genotype.
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Discussion:
It can be seen that even though the use of mitofusin as a genetic modifier helps partially restore
mitochondrial area and hence mitochondrial phenotype, this does not have any effect on the lifespan / growth curve and wire hang abilities of the Mfn1/2-/-HSA.Cre.Tg+/-rmd/rmd mice. A major
reason for the inability to perform the wire hang tests is the forelimb deformities in the Mfn1/2-/HSA.Cre.Tg+/-rmd/rmd mice that do not seem to be corrected, resulting in inability to grip and
hang on to the wire grid in the test. rmd mice show defects in membrane integrity as seen from
Evans Blue Fluorescent staining and JC-1 florescence assay (Sher et al., 2006)(Wu et al., 2010).
The mitochondria in the Mfn1/2-/-HSA.Cre.Tg+/-rmd/rmd mice have not been tested for
membrane integrity. Rescue of mitochondrial size could rescue membrane function and integrity,
which remains to be tested using the above-mentioned assays or the Seahorse cell analysis
technology.
This forelimb deformity was not corrected after the administration of S107 and hence these mice
were not tested for wire hang. S107 when administered to rmd mice did not seem to improve
growth curves as previously reported with the mdx mice, suggesting that oral supplementation of
S107 through Clear H2O diet gel did not show any improvement in rmd phenotype. An alteration
to the supplementation strategy via introducing the drug earlier in gestation to the pregnant
mothers in order to target muscular dystrophy of their mutant rmd offspring before its onset
might show a better response.
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Materials and Methods:
Growth Curve: In order to measure the body weight and hence the growth curve of mice an N
of 4 mice/sex/genotype were used for the experiments. The mice were weighed one at a time at
approximately the same time once a week. For weighing, an empty Lilly tub was pre-weighed
and used as a holder for mice in the weighing scale. The mice were then weighed and the weight
of the Lilly tub was subtracted to give the weight of the mice.

Wire hang: The wire hang assay was performed once a week at around the same time of day.
For this assay, the mice were placed on a wire mesh and the mesh then inverted. The stop watch
was started at the time when the wire mesh was inverted. The number of seconds for which a
mouse could hold on the mesh was recorded. An N of 4 mice/sex/genotype was used for each
experiment.

Mitochondria area analysis: For analysis of mitochondrial area, n=4 mice/sex/genotype were
used. Gastrocnemius muscles from the mice were prepared for TEM analysis as described in
chapter 2. About 5 pictures from each mouse were analyzed for mitochondrial areas. All the
mitochondrial areas analyzed from each group were pooled together and student’s t-test was used
to assess differences between mitochondrial areas between groups.

Transmission electron microscopic sample preparation, image analysis, were performed as
described in chapter 2.
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CHAPTER 5
CONCLUSION AND FUTURE DIRECTIONS

Medical management of muscular dystrophy
MD continues to affect many Americans (1 in 250,000) (Mercuri et al., 2002)
(www.mda.org, www.ninds.nih.gov). However, no cure exists. Medical management techniques
like cardiac care, provision of self-feeding support, implementation of techniques for safe
swallowing, physical therapy and other palliative care can be provided. Treatments are generally
tailored specific to patient needs by a team of physicians and they include occupational therapy
to improve muscle strength and function and speech therapy (National Organization of Rare
Disorders). Depending on the type and stage of MD, corrective surgery like cataract removal or
adding a pacemaker in cases of cardiac failure can be performed. Current medications used to
slow down the progression of MD symptoms are glucocorticoids like prednisone and Emflaza
that helps increase muscle strength, agility and slows down the progression of MD,
anticonvulsants to help with muscle spasms, immunosuppressants to help slow down the death of
muscle cells and antibiotics to treat respiratory infections, drugs like angiotensin converting
enzyme (ACE) inhibitors and beta blockers (www.nichd.nih.gov,
www.musculardystrophynews.com). Intraperitoneal injections of protease inhibitor leupeptin in
dy/dy mouse model for dystrophy prevented the development of any histological features of
muscular dystrophy (Tsuji & Matsushita, 1986).However, no further research has been
conducted in this therapeutic area. Myoblast transfer as a technique to replace dystrophin in
Duchenne’s muscular dystrophy patients showed no significant difference in muscle strength
and a low percentage of donor-derived dystrophin (Mendell et al., 1995). In the past decade,

97

gene therapy as a method of treatment of muscular dystrophy has gained momentum. Many
efforts have been made in the treatment of Duchenne muscular dystrophy (DMD) one of the
most common types of MD. Efforts for delivery of the mini or micro-dystrophin gene in DMD
patients are being made using vectors like adenoviruses, retroviruses plasmids and adenoassociated viruses with AAV vector mediated gene delivery being the most feasible with many
positive results in pre-clinical trials (Chamberlain, 2002) (Hollinger & Chamberlain,
2015)(Ramos et al., 2015). In another effort to help cure Duchenne muscular dystrophy, Serepta
therapeutics has been working on increasing expression of GALGT2 gene by AAV mediated
injections (www.musculardystrophynews.com). GALGT2 encodes for the protein GalNAc
transferase (beta 1,4 N-acetylgalactosamine galactosyltransferase) that transfers a complex sugar
molecule on to dystroglycan. In an mdx mouse, upregulation of GALGt2 gene via AAV vector
upregulates utrophin, which in turn prevents dystrophy (www.parentprojectmd.org)(Hirst,
McCullagh, & Davies, 2005). However, none of these therapies are FDA approved yet.

AAV mediated gene therapy for MDCMC
AAV is increasingly being used as a vector of choice for gene therapy in the alleviation
of MD symptoms. Retroviruses effectively integrate into the host genome but are difficult to
grow in large quantities thus inhibiting their use in gene therapy. Use of retroviruses for gene
therapy can be problematic in cases where retroviruses have been known to integrate into
promoter regions of oncogenic genes and cause tumorigenesis (RS, BF, SRW, P, & Chen H,
2004). Adenoviruses and plasmids have poor transduction properties when compared to AAV
vectors, making AAV vectors one of the most suitable forms of gene transfer systems. On the
other hand, AAV vectors can be used to carry genes up to 4.7Kb in size and can transduce post-
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mitotic cells, thus gaining specific importance in the field of MD therapy. Although not
common, studies have reported the generation of cellular immune response against protein
delivered by AAV. These immune responses can be limited by using muscle specific promoters
in case of muscular dystrophy patients (Cordier et al., 2001). For each case, a tissue specific
promoter can be inserted upstream of the AAV vector so as to have tissue specific effects and
lower host immune responses (Zeng et al., 2008)(B. Wang et al., 2008). Each AAV vector is
designed to carry a specific gene that the patient lacks making each vector specialized and
specific for the treatment of that particular MD (Chamberlain, 2002).

Therapeutic rescue of dystrophy in rmd mice
While our data contributes immensely to the current knowledge in the field of MDCMC,
many questions still remain unanswered. Deficiency of CHKB gene results in MDCMC as was
discovered from the study of the rmd mice. The rmd mice form a good model for MDCMC,
demonstrating most of the features of this disorder as seen from biochemical (Sher et al., 2006),
histology and muscle strength analysis. It is not known as to why deletion of a ubiquitously
present gene like choline kinase beta affects the mitochondria of the skeletal muscles
exclusively. Choline kinase beta deficiency should have effects on the membranes of all cellular
organelles but this is not apparent from histology of tissues like brain and heart of rmd mice,
whereas the skeletal muscles of the forelimbs show a less severe dystrophic phenotype. Levels of
PC in the hind limb skeletal muscles of rmd mutant mice are not depleted but severely reduced
(Sher et al., 2006), indicating that the hindlimb skeletal muscle tissues possibly derive PC via
some other pathway like the PE pathway in the liver. It will be interesting to know which
pathway compensates in choline kinase beta deficient conditions. Components of that pathway

99

can then be regulated using drugs to increase PC levels in MDCMC patients. As part of my
thesis, I have worked on the therapeutic rescue of rmd phenotype using mitofusin1 and 2 as
genetic modifier, using CDP-choline as a dietary supplement to bypass the defects in the
Kennedy pathway for PC synthesis, Using S107 as a dietary supplement to stabilize RyR1calstabin binding and thus improve rmd phenotype and by using gene therapy for the upregulation of choline kinase alpha and choline kinase beta in rmd muscle.

Therapeutic intervention using CDP-choline and S107 as oral supplements. Therapeutic
intervention in the form of oral supplementation of a Kennedy pathway intermediate like CDPcholine and that of a known RyR1-calstabin1 binding stabilizer-S107, failed to prevent
dystrophy in rmd mice. CDP-choline did not benefit life span of rmd mice and failed to rescue
rmd phenotype. Previous studies have shown that CDP-choline helps decrease creatinine kinase
levels in skeletal muscles of rmd mice (Wu et al., 2010). The pharmacokinetics of absorption of
CDP-choline in different tissues and testing of serum creatinine kinase levels in rmd mice
supplemented with CDP-choline will help determine improvements in muscle condition that
were not visible through gross phenotype studies. Analysis of muscle force of contraction in fasttwitch muscle groups like the EDL can sensitively determine improvements in muscle force and
contraction which are not visible in tests like wire hang.
S107 has been shown to help improve muscle excitation and contraction force in mouse
models of Duchenne muscular dystrophy (Andersson et al., 2011)(Andersson et al., 2012)(Blat &
Blat, 2015). Supplementation of S107 compound in diet did not lead to improvements in gross
wire hang abilities or weights of the rmd mice. Like with the CDP-choline supplemented mice, it
will be beneficial to assess the muscle force of contraction in fast-twitch muscle groups like the
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EDL muscle. These tests will help determine if improvements in muscle force and contraction
abilities will help translate to better quality life in MDCMC patients.

Use of Mitofusin 1 and Mitofusin 2 as genetic modifiers in rmd: Use of Mfn1/2 as a gene
modifier, led to partial rescue of the mitochondria, with mitochondrial areas in between that of
rmd and WT mice but failed to rescue dystrophy and increase life span of rmd mice.
Mitochondria in rmd mice show decreased membrane potential and are not as efficient as
mitochondria in WT mice (Sher et al., 2006)(Wu et al., 2010). The partially rescued
mitochondria in Mfn1/2HSA.Cre+/-rmd/rmd mice have not been tested for membrane integrity or
function. Performing these tests on the Seahorse cell analysis machine can help understand if the
partial mitochondria showed a rescue in function. Improvements in membrane function would
lead to further confirmation of our findings; that, megamitochondria, by itself does not rescue
rmd but may contribute to other characteristics of the disorder arising due to choline kinase beta
and hence PC deficiency.

Gene therapy by up-regulation of Chkb: The Tg-rmd showed muscle strength, mitochondrial
phenotype and life span comparable to that of WT mice. A 14-fold increased expression of Chkb
gene does not cause cellular damage and hence, systemic overexpression of Chkb can be targeted
as a possible gene therapy. This led to testing of AAV mediated gene therapy for the rescue of
dystrophy in rmd mice. For treating rmd in our mouse models, I have not used a muscle specific
promoter but have conducted intra-muscular injections, in order to circumvent the construct size
restrictions, since our Ttn promoter along with our Chka or Chkb gene far exceeds the 4.7 kb
carrying capacity of the AAV vector (Maddatu et al., 2005b). AAV-Chkb gene therapy,
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intramuscular injections in the gastrocnemius muscles of rmd mice improved muscle fiber
regeneration, leading to increased fiber area, decrease in the number of centralized nuclei and
increased muscle weight. This indicates that upregulation of AAV-Chkb in MDCMC can be
targeted as a potential therapy, however, in order to design a therapy that can be FDA approved,
testing of a few more factors is necessary. It is essential to test for effects of systemic injections
in rmd mice. Even though, my experiments indicate that over-expression of Chkb gene in Chkb
deficient rmd mice does not cause immediate toxic effects, it is essential to perform an aging
study on systemically injected mice, in order to test for long-term toxic or immunogenic effects
that may occur. Along with this study, it will be interesting to note whether, AAV-Chkb
injections in 8 week rmd mice would result in similar improvements in muscle health and
phenotype. This experiment can test for percent regeneration of muscle fibers compared to 3week injected mice and help understand if injection of adult MDCMC patients can be beneficial
for delaying progression of dystrophy and can help with increased muscle strength.

Gene therapy by up-regulation of CHKA: AAV mediated injections of CHKA gene resulted in
similar improved muscle regeneration, decreased number of centralized nuclei and increased
muscle weight as with the AAV-Chkb injections, indicating that Chka can also be a potential
target for the rescue of dystrophy. Since MDCMC is caused due to deficiency in choline kinase
beta gene, upregulation of choline kinase beta will be the preferred mode of therapy in MDCMC
patients. AAV-Chka injections can be administered in the rare possibility of development of an
immune reaction to AAV-Chkb injections or in the event, that a second injection is required after
a few years of administering the first injection with AAV-Chkb. For use as a gene therapy
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vector, it is necessary to test for long-term effects of systemic injections of Chka in rmd and
unaffected mice.
In order to minimize off-target transduction, AAV vectors carrying Chka or Chkb gene of
interest under a muscle specific promoter, other than Ttn can be used. Thus, the vector can be
made specific for treatment of muscular dystrophy caused as a result of Chkb deficiency. Muscle
creatinine kinase (MCK) has been shown to have success as a muscle specific promoter in gene
therapy for Duchenne muscular dystrophy (Cordier et al., 2001)(B. Wang et al., 2008).

Implication of choline kinase alpha in cancer: Choline kinase alpha gene has been studied more
extensively than choline kinase beta gene due to its implication in cancer. CHKA expression is
the lowest in adult human skeletal muscle (GETx Portal Version V7). Interestingly, in mice,
Chka expression in skeletal muscle tissues decreases in a rostro-caudal gradient with an increase
in mouse age (Wu et al., 2010) (Gallego-Ortega et al., 2009). Decrease in choline kinase alpha
expression in adult skeletal muscle tissues implies that choline kinase alpha is detrimental to
healthy skeletal muscle tissues. Choline kinase alpha is overexpressed in 40-60% of human
tumors (X. Chen et al., 2017). Transfecting Hek293T with choline kinase alpha leads to
anchorage independence similar to that obtained with Rho-A induction. However, up-regulating
CHKA expression in adult skeletal muscle tissues using AAV mediated gene therapy does not
show any immediate toxic effects in the rmd or unaffected mice. This implies that choline kinase
alpha may not be the causative agent in tumorigenesis but a possible indicator of the same.
Hence, up-regulation of Choline kinase alpha to rescue can be a potential therapeutic strategy for
the rescue of rmd phenotype.
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The mechanism behind decrease in CHKA expression in adult skeletal muscles of
humans and a complete shut-down of Chka expression in adult skeletal muscles of mice is not
known. Epigenetic changes like DNA methylation can bring about a decrease in gene expression.
De novo methylation of CpG islands has been known to contribute to gene silencing (Jaenisch &
Bird, 2003). Many diverse classes of RNA have been shown to recruit histone and DNA
methyltransferases, thus silencing DNA/gene expression (Holoch & Moazed, 2015). Methylation
of choline kinase alpha gene sequence can be determined with array of bead hybridization
followed by a higher resolution method like HPLC and mass spectrometry to determine the exact
percentage of sequence methylated. These assays can be performed at 1, 2, 4, 6 and 8 week old
mice on order to determine the period when these epigenetic changes begin to occur in mice
(Kurdyukov & Bullock, 2016). DNA methylation has been shown to be inhibited in vitro in cell
culture using chemical compounds like 5-Aza-2’-deoxycytidine, caffeic acid and chlorogenic
acid. It will be interesting to see whether these compounds can help inhibit DNA methylation of
choline kinase alpha, preventing it’s shut down and thus rescuing rmd phenotype in choline
kinase beta deficiency. This strategy can also be applied to MDCMC patients in order to
decrease shut down of CHKA expression, prevent drastic decrease in PC levels and hence
prevent or reverse muscular dystrophy caused as a result of CHKB deficiency.

Differential function of Chka and Chkb: enzymatic properties of Choline kinase alpha and beta
have shown that choline kinase beta has a Michaelis constant (Km) for choline 2.8 times higher
than choline kinase alpha 1. The Km of choline kinase beta is lower than that of choline kinase
alpha 1 for ethanolamine. This suggests that in cell free systems, choline is a better substrate for
choline kinase alpha 1 and ethanolamine is a better substrate for choline kinase beta (Gallego-
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Ortega et al., 2009). This is different for different tissues. In mice, we know that choline kinase
beta is responsible for the phosphorylation of choline since choline kinase alpha is shut down
(Wu et al., 2010b). The activity of choline kinase in a given cell type is regulated not by its
amounts but by the combination of each isoform subunit to form functional homodimers or
heterodimers (Aoyama et al., 2004). It has been speculated that the alpha/beta heterodimer may
have a specific activity in between that of the two respective homodimers. A common conclusion
from in vitro and in vivo studies suggests that the main fate of choline is the synthesis of PC via
the Kennedy pathway, accounting for the use of 95% of total choline pool in most tissues
(Gibellini & Smith, 2010).

Expression patterns of Chka and Chkb in different tissues: Though research on the
expression levels of different homo and heterodimers of choline kinase alpha and beta need to be
performed, it can be implied that alpha and beta paralogs can compensate for each other. Thus, in
the skeletal muscles of mice, where there is shut down of choline kinase alpha expression,
complete lack of choline kinase beta results in extremely low levels of PC and hence muscular
dystrophy. The forelimb shows low/remnant levels of choline kinase alpha expression and hence
are less affected in choline kinase beta deficient conditions. In rmd mice, the cortex and midhind brain tissues shows undetectable levels of Chkb expression but show minute levels of Chka
expression in comparison to C57BL/6 mice (0.24 and 0.0005 fold, respectively) (Supplemental
fig 5-6) . Tg-rmd mice show 0.23 fold and 0.8 fold expression of Chka compared to C57BL/6
mice in the Mid-Hind brain region. Chkb expression levels for the Mid-Hindbrain region are 0
and 0.38 for rmd and Tg-rmd mice. This data indicates that different regions of the brain have a
specific pattern of Chka and Chkb expression which influence cognition, membrane fluidity and

105

structure. This data along with the cognitive analysis on the Tg-rmd and rmd mice suggests that
in Chkb deficient conditions, there remains expression of Chka in regions of the brain and while
it has not been identified whether this Chka expression is from neural cells or vasculature, it can
be suggested that this expression influences development of cognitive phenotype in these mice.

Absence of cognitive impairments in rmd mice
Based on my thesis research, the rmd mutant mice do not show signs of cognitive impairment in
any of the behavioral assays I examined them on. This could be because these mice were tested
at a very early age, not having developed working memory or learning problems. However,
children at the age of about 5 years were shown to have a lower performance on certain learning
tests and tests for IQ (Mitsuhashi, Ohkuma, et al., 2011)(S. Sparks et al., 2012). MDCMC
patients showed prominent speech defects which were not tested for in rmd mice. Going further,
we could test the Tg-rmd mice for other disorders within the spectrum of cognitive impairments
observed in MDCMC patients such as speech impairments and interaction with a strange mouse
or object in order to gain a better understanding of social interaction and hence, of the presence
of multiple aspects within the cognitive impairment spectrum. As mentioned in chapter 3,
background strains have a significant influence over behavioral assays. Using a different
background strain like FVB or DBX could significantly alter the results of the spontaneous
alternation, spontaneous alternation with delay and paired associates learning tests (Hall &
Roberson, 2012)(Brodkin et al., 2004)(Lassalle et al., 2008). Real time PCR analysis on the
cortex and mid-hind brain tissue showed a 0.4 fold expression of Chkb gene in the cortex and a
0.8 fold expression in the mid-hind brain region in the Tg-rmd mice when compared to
C57BL/6J (Supplemental Fig 5). This expression is absent in the rmd mice. Further tests need to
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be performed in order to determine if this expression of transgenic Chkb gene is within a certain
population of neuronal cells or in the glial, endothelial or vascular smooth muscle cells of the
brain. Culturing neurons from Tg-rmd mice and testing them for the expression of Chkb gene
would help determine expression in that cell population alone. PCR markers specific to
transgenic Chkb and endogenous Chkb will help distinguish between the two expressed genes in
the cells. Presence of reliable antibodies for Chka and Chkb can enable immunostaining of cross
sections of the brain in order to determine the regions of expression of the two respective genes.
Another method of determining the regional specific expression of Chka and Chkb is by using
techniques like RNA in situ hybridization in which, single stranded RNA probes which bind to
complementary nucleic acid sequences are used to help detect the genes or mRNA of interest.
This can enable visual detection of Chka and Chkb in various tissue cross sections.

Summary of contributions to the field
Choline kinase beta deficiency causes lack of PC synthesis which results in muscular dystrophy.
The rmd mouse discovered in our lab, has a spontaneous 1.5 kb deletion in the choline kinase
beta gene, develops muscular dystrophy in a rostro-caudal gradient and shows megamitochondria
like the MDCMC patients, providing an excellent model organism for the further study of
MDCMC. In the various attempts to rescue rmd phenotype in mice, it was observed that, even
though oral supplements and compounds do not seem to rescue dystrophy, further analysis can
confirm if these compounds can be used for increasing muscle strength and hence the quality of
life in MDCMC patients. Rescuing mitochondrial area does not rescue dystrophy in rmd mice,
providing further confirmation that the dystrophy results due to deficiency in choline kinase beta
gene and hence, in, PC synthesis and not as a result of the megamitochondria disrupting normal
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muscle architecture. Thus, muscular dystrophy in rmd and hence MDCMC can be rescued using
gene therapy by upregulating choline kinase beta expression levels for the production of the
necessary PC molecule. Even though there is a decrease in the expression of gene paralog Chka
in adult murine skeletal muscles, there appears no immediate toxic effects of the upregulation of
choline kinase alpha in mouse adult skeletal muscles via AAV mediated gene therapy. It appears
that choline kinase alpha homodimers can compensate for PC production in Chkb deficient
conditions. rmd mice show brain lipid changes consistent with those observed in Alzheimer’s
Disease patients, patients with mild cognitive impairments and brain trauma victims, however,
these lipid changes do not translate to behavioral differences when tested on a battery of
behavioral assays, indicating a secondary mechanism of PC synthesis in rmd brain tissue or
mouse background strain influence. Correcting for background strain influence can make the
rmd mouse a complete model for the study of MDCMC. Together, my research has added to the
field of knowledge pertaining to MDCMC by way of creating a database of lipid changes
occurring in choline kinase beta deficient conditions and by way of engineering and testing a
gene therapy for the rescue of muscular dystrophy as a result of choline kinase beta deficiency.
This gene therapy study can be further expanded upon for translation into MDCMC patients.
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Appendix A: Chapter 2 Supplemental data

SUPPLEMENTAL FIG 1. Dietary supplementation of CDP-choline for the rescue of rmd
phenotype: Dietary supplementation of CDP-choline rmd mice did not show a significant
increase in body weights of male or female mice tested (A)(B). Mass spectrometric analysis
of the amount of CDP-choline in the muscle of the rmd mice post CDP-choline
supplementation for a period of 71 days did not show significant differences between the
groups analyzed (C) indicating that there were no beneficial effects of CDP-choline
supplementation, where WT indicates +/+ littermates on CDP-choline diet, Control
indicates rmd/rmd mice on normal diet and Test indicates rmd/rmd mice on CDP-choline
supplemented diet. N = 4 mice/sex in WT, 4 mice/sex in control and 8 mice/sex in test. Diet
supplementation was initialized at 3 weeks of age and continued for a total of 12 weeks.
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SUPPLEMENTAL FIG 2: Evidence of rmd phenotype at 2 and 4 weeks:
At 2 weeks: rmd mice show disturbed muscle fiber architecture with megamitochondria (A)
compared to WT mice (B). Number of mitochondria are significantly lower with p<0.0001
(C). Mitochondrial areas are significantly larger in rmd mice at 2 weeks with p<0.0001 (D).
N= 4 mice/sex/genotype. Error bars represent mean and SD.
At 4-5 weeks: The rmd males (E) and females (F) showed a significant difference compared
to the WT in the total distance travelled (p=0.02 in males and 0.04 in females) and in the
vertically activity shown (p-0.001 in males and 0.003 in females) (G-H). On the rotarod
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assay, rmd mice show a significant difference from WT in latency to fall with p<0.0001 (I)
in a grouped analysis of males and females. rmd mice show significantly decreased fore-paw
and all-paw grip strength when compared to their unaffected (WT) littermates with males
and females showing p values less than 0.0001 in each of the tests (J-K), suggesting lower
grip and hence muscle strength. N= 4-6 mice /sex/genotype. Error bars represent mean and
SD.

SUPPLEMENTAL FIG 3: Effects of gene therapy on rmd muscle: H&E staining of AAVChkb injected gastrocnemius muscle in rmd mice shows restoration of muscle structure in
injected leg (A) vs in the uninjected leg (B). As seen in AAV-Chkb injected gastrocnemius
muscle, AAV-Chka injected gastrocnemius muscle of rmd mice also look bigger and
bulkier when compared to saline injected rmd muscle (C). AAV-Chka injected rmd
muscles shows presence of fluorescent EGFP reporter, whereas no fluorescence is observed
in saline injected rmd muscle (D). Autofluorescence can be detected in the feet and bladder
region but is not significant to the study. H&E staining further provides evidence of
restoration of muscle phenotype in the AAV-Chka injected muscle (E) compared to the
sham injected muscle (F).
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SUPPLEMENTAL FIG 4: Montaged image of AAV-Chka injected rmd muscle: Cross
section of gastrocnemius muscles from AAV-Chka injected rmd mouse shows significant
and partial restoration of muscle structure and phenotype in AAV-Chka injected muscle
(E) compared to the dystrophic muscle architecture of sham injected muscle (F). Both E
and F represent Fiji stitched images whereas, inset pictures are at 20X magnification and
indicate the nature of partial restoration of muscle phenotype in AAV-Chka injected rmd
muscle.

112

Appendix B: Chapter 3 Supplemental data :
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Supplemental Fig 5. Realtime PCR for detection of Chkb levels in brain tissue: Real time
PCR in the cortical tissue of rmd mice showed a no expression of Chkb, whereas, tissue
from rmd/+, Tg-rmd and Tg-WT mice showed levels of 0.29, 0.42 and 0.89 respectively, on
comparison to C57BL/6J mice. In the mid+hind brain tissue rmd mice showed no
expression of Chkb gene whereas, tissue from rmd/+, Tg-rmd and Tg-WT mice showed
levels of 0.39, 0.38 and 1.95 respectively, on comparison to C57BL/6J mice.
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Appendix C: Chapter 5 Supplemental data:
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Supplemental Fig 6. Realtime PCR for detection of Chka levels in brain tissue:
Real time PCR in the cortical tissue of C57B/6J, rmd/+ (Het), Tg-rmd, rmd and Tg-WT
mice showed a 0.45-fold expression in Tg-rmd mice and a 0.23-fold expression in rmd mice.
Rmd/+ and Tg-WT mice showed expression levels of 0.32 and 0.67 respectively. In the MidHind brain region Tg-rmd mice showed a 0.81-fold expression of Chka and rmd mice
showed negligible expression levels of 0.00052. The rmd/+ and Tg-WT mice showed
expression levels of 0.52 and 1.22 respectively. This shows that in Chkb deficient
conditions, rmd mice show expression of Chka in some regions of the brain, which may
influence cognition, membrane fluidity and structure in the brain.
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